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Evolution of myelin has enabled rapid impulse propagation and development of complex 
brain circuitry. However, the in vivo mechanisms that trigger and orchestrate proliferation of 
oligodendrocyte precursor cells (OPCs), differentiation of OPCs into oligodendrocytes, and 
myelination in central nervous system (CNS) have remained unclear. Neuregulin-1/ErbB 
signaling, which controls virtually all aspects of peripheral myelination by Schwann cells is 
not essential for myelination in the CNS. Moreover, the identification of several 
promyelination factors made by astrocytes and microglial cells, the responsiveness of 
oligodendrocytes to ubiquitously expressed growth factors and their ability to myelinate 
artificial nanofibers has raised questions about the cellular origin of the key signals that 
control CNS myelination. To particularly address the impact of axonal signals in vivo, we 
studied the cerebellum of mice, in which the axons of granule cell neurons (referred to as 
“parallel fibers”) within the molecular layer are naturally of small caliber and unmyelinated. 
By conditional inactivation of the lipid phosphatase PTEN, we experimentally enhanced 
PI(3,4,5)P3-dependent Akt/mTOR downstream signaling specifically in granule cells, which 
subsequently lead to a significant increase in parallel fiber (Pf) diameters. Most importantly, 
this increase was tightly associated with the proliferation of OPCs, the differentiation of 
oligodendrocytes in the molecular layer, and the de novo myelination of up to 40% of all Pf 
at 1 year of age. While the synaptic input to OPCs was unchanged, gene expression 
profiling of laser captured mutant granule cell layers identified proteins, such as FGF1, 
Pleiotrophin, Timp3, Thymosin beta 4, and Activin A, as novel regulators of OPC 
proliferation, oligodendrocyte differentiation, and/or myelin growth. We conclude that 
activation of neuronal, PI(3,4,5)P3-dependent downstream signaling pathways can be 







2.1. The central nervous system 
The nervous system serves as a control center between the inner and the outer world. 
Composed of the central nervous system (CNS) and the peripheral nervous system (PNS), 
it constantly receives information, processes highly complex mechanisms and reacts in 
diverse patterns of behavioral control. The CNS is built by a variety of different cell types 
and is comprised of brain and spinal cord. It can be divided into white and gray matter. 
White matter mainly consists of myelinated fiber tracts and glial cells, while the gray matter 
is formed by neuronal cell bodies, dendrites and primarily unmyelinated axons. 
Glial cells in the mammalian CNS can be subdivided into astrocytes, microglia, 
oligodendrocytes and chondroitin sulfate proteoglycan expressing NG2-Glia (Kettenmann 
and Ransom, 2005; Staugaitis and Trapp, 2009). Astrocytes usually exhibit a star shaped 
morphology and serve distinct functions, for example, the biochemical support of endothelial 
cells (the blood brain barrier forming cells), the support of neurons by transferring nutrients 
(e.g. lactate) and the removal of neurotransmitters from the synaptic cleft (Kettenmann and 
Ransom, 2005). Microglia cells are the resident innate immune cells of the CNS and are 
able to remove cellular debris or even parts of damaged cells (Kettenmann and Verkhratsky, 
2011). Oligodendrocytes wrap long segments of axons with multilayered sheaths of 
extended cell membrane, the so-called “myelin sheaths” (Nave, 2010). By insulating axons 
at the internodes and thereby restricting action potentials to the nodes of Ranvier, they are 
providing the basis for the fast saltatory conduction of action potentials (Baumann and 
Pham-Dinh, 2001; Kettenmann and Ransom, 2005). Myelinated axons accelerate nerve 
conduction 20-100-fold compared to unmyelinated axons of the same diameter (Nave and 
Werner, 2014). Furthermore, reduced transverse capacitance and increased transverse 
resistance of the axonal plasma membrane is demonstrated by axons ensheathed with 
myelin. The restriction of action potentials to nodes of Ranvier reduces the ATP-dependent 
Na+/K+ exchange in preserving the resting potential of axonal membranes. In addition, 
oligodendrocytes maintain long-term axonal integrity and provide trophic axonal support. 
This is especially important for longer axons, where some myelinated segments can be 
even several meters away from the neuronal soma (Funfschilling et al., 2012; Lee et al., 









Myelination is an ongoing process that starts around birth and continues into the third 
decade of life in humans (Miller et al., 2012). During development, oligodendrocytes evolve 
from precursor cells that migrate throughout the spinal cord and brain, before they 
differentiate into postmitotic pre-myelinating oligodendrocytes and finally into myelin 
forming oligodendrocytes (Fig. 1). Oligodendrocyte precursor cells (OPCs) are produced 
from neuroepithelial cells in several distinct spatiotemporal waves in the spinal cord and 
brain (Rowitch and Kriegstein, 2010) and can be identified by the expression of marker 
proteins such as the NG2 proteoglycan and platelet-derived growth factor receptor alpha 
(PDGFRa). They remain to be present and are evenly distributed throughout the gray matter 
and white matter in the adult CNS (Kirby et al., 2006). 
 
 
Fig. 1. Oligodendrocyte lineage cell development. Oligodendrocyte progenitor cells (OPCs) 
differentiate into multipolar premyelinating oligodendrocytes, which finally mature into myelinating 
oligodendrocytes. OPCs compose the majority of mitotic cells in the adult brain. Mature 
oligodendrocytes are the myelin forming glia cells in the CNS and are able to myelinate multiple 
axons simultaneously (adapted image from Fields, 2015). 
 
Mature oligodendrocytes are capable of forming myelin sheaths that cover between 20 and 
60 different axonal segments (Chong et al., 2012; Hildebrand et al., 1993; Matthews and 
Duncan, 1971) (Fig. 2a). In contrast, Schwann cells, the myelin forming glia cells in the 
PNS, are bipolar and enwrap only one axonal segment each. Data from zebrafish 
experiments suggests, that the wrapping of single axonal segments takes only a couple 
hours (Czopka et al., 2013). The half-life of myelin proteins is very long and myelinating 
oligodendrocytes can remain for more than 5 decades in humans (Savas et al., 2012; Yeung 
et al., 2014). Nevertheless, OPCs are also abundant in the mature brain, and account for 





and differentiate into mature myelinating oligodendrocytes (Richardson et al., 2011). that 
for example replace dying oligodendrocytes or intercalate among existing myelin sheaths. 
Furthermore, adult-born oligodendrocytes, might be involved in the myelination of 
previously unmyelinated axons and thereby contribute to neuronal plasticity. In humans and 
mice there is evidence, that myelin remodeling contributes to motor learning (McKenzie et 
al., 2014; Yeung et al., 2014; Young et al., 2013). For example, changes in white matter 
structures could be correlated with extensive piano practice and juggling (Hu et al., 2011; 
Scholz et al., 2009). 
Myelin is a highly specialized, fundamental compartment of the oligodendrocyte, which can 
further be subdivided in compact and non-compact myelin (Arroyo and Scherer, 2000; 
Poliak and Peles, 2003). Compact myelin consists of several layers of adhesive plasma 
membrane. Proteolipid protein (PLP) is the most abundant protein of the CNS myelin, with 
a role in the compaction, stabilization and maintenance of myelin sheaths (Boison et al., 
1995; Klugmann et al., 1997). Analysis of mice lacking PLP and its splice isoform DM20 
revealed physically unstable CNS myelin (Boison et al., 1995; Klugmann et al., 1997). In 
patients, mutations in the PLP gene causes Pelizaeus-Merzbacher disease (PMD), an X-
linked dysmyelinating disorder (Inoue et al., 1996). Another essential adhesion protein is 
Myelin basic protein (MBP) (Dupouey et al., 1979), with a potential zipper function for the 
cytoplasmic leaflets (Nawaz et al., 2009). In mutant mice lacking MBP expression (shiverer), 
oligodendrocytes fail to assemble compact myelin and display  hypomyelination in the CNS 
(Rosenbluth, 1980). The non-compact myelin compartment is lacking these adhesion 
proteins and is comprised of adaxonal myelin, abaxonal myelin, paranodal loops and 
additional nanochannels (Fig. 2b). Paranodal loops form septate-like junctions (SpJ) with 
the axonal membrane and directly influence the distribution of sodium channels at the node 
of Ranvier and potassium channels at the juxtaparanode (JXP) (Poliak and Peles, 2003; 
Rasband, 2011). A large proportion of the axon at the juxtaparanodes and the internodes 







2.3 Regulation of myelination 
Suggestively, differentiation of oligodendrocytes and myelination is regulated by a plethora 
of intrinsic and extrinsic cues. These signals include growth factors, protein kinases and 
extracellular matrix molecules, influencing epigenetic modifications, transcriptional and 
translational regulation and the actin cytoskeleton in oligodendrocytes (Bercury and 
Macklin, 2015). In contrast to cultured Schwann cells, which clearly require axonal signals 
for differentiation, oligodendrocyte development, at least in vitro, follows more a “default 
pathway”. Oligodendrocytes can differentiate and even produce myelin components in the 
absence of neurons and axons (Dubois-Dalcq et al., 1986; Mirsky et al., 1980; Temple and 
Raff, 1986). Later it was shown that they can even myelinate artificial carbon nanofibers 
and micropillars (Lee et al., 2012; Mei et al., 2014). These findings may raise the question 
to which extend axonal signals are required at all to regulate oligodendrocyte differentiation 
and myelination. On the other hand, several lines of experiments have indeed suggested 
an instructive role of neuron-derived signals at various stages of oligodendrocyte 
development in vivo (Barres and Raff, 1999; Simons and Trajkovic, 2006; Taveggia et al., 
2010). For example, killing axons significantly reduced the number of oligodendrocytes and 
supplying the transected optic nerve with exogenous ciliary neurotrophic factor (CNTF) 
prevented the reduction of oligodendrocytes (Barres et al., 1993). Transgenic mice, in which 
the number of optic nerve axons was genetically increased also harbored more 
oligodendrocytes (Burne et al., 1996). In other experiments electrical activity of axons has 
increased the number of OPCs and supported myelination, possibly as a response to the 
axonal release of adenosine (Barres and Raff, 1993; Demerens et al., 1996; Gibson et al., 
2014; Stevens et al., 2002). However, in contrast to Schwann cells, which are always in 
close axonal contact during migration CNS oligodendrocyte lineage cells develop largely 
without close axonal contact. Myelination in the CNS begins with OPC recruitment and 
expansion, followed by oligodendrocyte differentiation, all steps without axonal contact. 
Different growth factors and cytokines, including Pdgf, Fgf2, Igf1, Bdnf, Nt3, Cntf and Lif, 
have been identified over the last decades as regulators of the proliferation and 
differentiation of oligodendrocyte lineage cells (Baron et al., 2005; Barres and Raff, 1994; 
Carson et al., 1993; Ishibashi et al., 2006; Miller, 2002). 
Fig. 2. Structure of myelinated axons in the CNS. (a) Oligodendrocytes cover multiple axonal 
segments and provide the basis for saltatory signal propagation. (b) Schematic longitudinal cut 
through a myelinated fiber heminode. The node, paranode, juxtaparanode (JXP) and internode are 
labelled and are structurally specialized axonal segments upon myelination (modified image from 






Most of these identified factors are produced by astrocytes. However, in vitro experiments 
also revealed the capability of endothelial cells to promote the survival and proliferation of 
OPCs by soluble growth factors (Arai and Lo, 2009). In contrast to the PNS, no neuronally 
expressed “regulator” has been identified so far that would control myelination in the CNS. 
With respect to it's instructive role in PNS myelination, a possible candidate, however, was 
neuronal Neuregulin1 (Nrg1). This axonal growth factor activates ErbB receptor tyrosine 
kinases on glial cells, and is required for Schwann cell survival, differentiation and 
myelination (Jessen and Mirsky, 2005; Michailov et al., 2004; Nave and Salzer, 2006; 
Taveggia et al., 2005). The role of Nrg1 in the CNS is still somewhat controversially 
discussed. Earlier reports suggested a role for Nrg1 and ErbB receptors in OPC 
proliferation, oligodendrocyte survival, and myelination (Taveggia et al., 2008; Vartanian et 
al., 1999). However, intensive genetic analyses of mice lacking Nrg1 from CNS neurons or 
the corresponding ErbB3/4 receptors from oligodendrocytes revealed normal 
oligodendrocyte numbers and intact CNS myelination  (Brinkmann et al., 2008). Neuronally 
expressed proteins that are able to influence oligodendroglial functions can also be found 
in the group of secretases. Disintegrin and metalloprotease (ADAM) proteins have been 
implicated in PNS myelination (Sagane et al., 2005; Wakatsuki et al., 2009). The β-site 
amyloid precursor protein cleaving enzyme 1 (BACE1) demonstrated a role in PNS and 
CNS myelination (Hu et al., 2006; Willem et al., 2006). Oligodendrocyte development in the 
CNS can furthermore be limited by interaction between Jagged-Notch. Jagged is expressed 
by neurons at early developmental stages and by binding to Notch1 (only expressed by 
oligodendrocytes) OPC differentiation and myelination is inhibited (Genoud et al., 2002; 




Phosphatase and tensin homolog (Pten) is a tumor suppressor gene that was first 
discovered by Li et al. 1997 in a variety of different breast, prostate gland and brain tumors 
(Li et al., 1997). The protein encoded by this gene is a phosphatidylinositol-3,4,5-
trisphosphate 3-phosphatase. PTEN antagonizes the PI3K induced activation of Akt/mTor 
downstream signaling, by converting PIP3 (Phosphatidylinositol (3,4,5)-trisphosphate) into 
PIP2 (Phosphatidylinositol-4,5-bisphosphat) (Stiles et al., 2004b; Suzuki et al., 2008). Loss 
of PTEN function leads to over-activation of Akt and in general a hyperactivated PI3K 
downstream signaling as a consequence of accumulation of PIP3 in the plasma membrane 
(Cantley and Neel, 1999) (Fig. 3). In several in vivo studies the deletion of PTEN in neurons 





Groszer et al., 2001; Kwon et al., 2006). Differentiated neurons of the cerebral cortex and 
hippocampus lacking PTEN elicited a macrocephaly in mice and a neuronal hypertrophy 
(Kwon et al., 2001). Transgenic mice expressing Cre-recombinase under a GFAP promotor 
crossed to mice with floxed PTEN, resulted in PTEN deletion primarily in astrocytes, 
cerebellar granule cells and granule cells of the dentate gyrus of the hippocampus. Similar 
to findings in human Lhermitte-Duclos disease (LDD), this genetic modification induced 
enlarged brains, increased neuronal cell size and lead to abnormal neuronal organization 
(Backman et al., 2001; Kwon et al., 2001). LDD is a rare brain tumor, also known as 
dysplastic cerebellar gangliocytoma and is characterized by abnormal development and 
enlargement of the cerebellum. Although the exact cause in patients is unknown, mutations 
in the PTEN gene have been identified (Blumenthal and Dennis, 2008). Astrocytes, next to 
neurons show a similar cell growth when PTEN is deleted specifically in astrocytes in the 
cerebral cortex (Fraser et al., 2004). In mouse mutants selectively lacking PTEN in 
oligodendrocytes enlargement of all white matter tracts and hypermyelination at the single 
cell level was a prominent finding (Goebbels et al., 2010). Similar, the ablation of PTEN in 
from Schwann cells caused a hypermyelination of small-caliber axons and a focal 
hypermyelinating pathology in larger axons (Goebbels et al., 2010; Goebbels et al., 2012).  
 
 
Fig. 3. Schematic diagram depicting the PI3K/Akt pathway. Binding of growth factors to G protein-
coupled receptors and tyrosine kinase receptors (RTKs) triggers the phosphorylation of PIP2 by PI3K 
to generate PIP3. PTEN is the antagonist of PI3K and removes the 3′ phosphate of PIP3. Activated 
PDK1 phosphorylates AKT and promotes survival, migration, cell cycle progression, and cell growth 








2.5 The architecture of the cerebellum 
The cerebellum is a structure of the CNS and plays an important role in motor control. 
Cerebellar dysfunctions often present with motor abnormalities, such as ataxia. 
Coordination, precision and timing of movements are associated with the cerebellum. The 
vermis, a narrow midline area, divides the cerebellum into two hemispheres. The 
cerebellum consists of the cerebellar cortex and the deep cerebellar nuclei (DCN). Tightly 
folded layers of the cortex, with white matter underneath form the gross anatomy of the 
cerebellum. The cytoarchitecture is highly uniform and characterized by the molecular layer 
(ML), the Purkinje cell layer (PL) and granular cell layer (GL) (Fig. 4a). The ML is the 
outermost layer and contains stellate and basket cell interneurons. Parallel fibers (Pf), the 
granule cell axons, form a large number of excitatory synapses onto the dendrites of 
Purkinje cells and dendrites of basket cells and stellate cells. Pf belong to the thinnest 
known vertebrate axons and are normally unmyelinated, possibly because their size is 
below a critical threshold. From mouse to macaque, the average unmyelinated Pf diameter 
is between 0.2 μm and 0.3 μm and it scales up slightly with brain size (Wyatt et al., 2005) 
(Fig. 4b). The PL contains the large Purkinje cell bodies the Bergmann glia. Purkinje cell 
dendrites harbor a larger number of spine branches spreading up into the ML. Each Purkinje 
cell can be innervated by 100000-200000 parallel fibers (Ito, 2006). Additionally, and in 
contrast to the high number of parallel fiber inputs, Purkinje cells receive input from exactly 
one climbing fiber of the inferior olivary nucleus (Barmack and Yakhnitsa, 2011). The GL 
contains the cell bodies of the small granule cells, unipolar brush cells and the Golgi cells. 
The mossy fibers form excitatory synapses with the granule cells and the cells of the 
cerebellar nuclei (Nicoll and Schmitz, 2005). Granule cells are the most abundant neurons 







Fig. 4. The cerebellar cytoarchitecture. (a) The cerebellum can be clustered into the molecular 
layer, the Purkunje cell layer, the granule cell layer and underneath the cerebral cortex, the white 
matter. (b) The diagram elucidates the inputs from parallel fibers onto a Purkinje cell. Parallel fibers 
are the unmyelinated axons from the granule cells (modified image from Purves, 2012). 
 
 
2.6 Cerebellar PTEN mutants 
Throughout the body, the genetic loss of Pten can trigger enhanced mTOR-dependent cell 
growth (Backman et al., 2001; Fraser et al., 2004; Groszer et al., 2001; Kwon et al., 2006). 
Preliminary results were generated by B. Weege and Dr. A. Pieper (in the Department of 
Neurogenetics, subgroup "Developmental Neurobiology") by Intercrossing Pten-floxed mice 
(Lesche et al., 2002) with mice that express Cre recombinase (under control of the GABAA 
receptorα6 subunit promoter) selectively in cerebellar granule cells (Funfschilling and 
Reichardt, 2002). Experimental inactivation of Pten enlarged cerebellar granule cells and 
their axons (Fig. 5a). The diameter of parallel fibers increased over time, as quantified by 
electron microscopy (EM), reaching 0.61±0.009 µm in Tg(m6)-Cre*PtenloxP/loxP mice 
(mutant) over 0.16±0.002 µm in PtenloxP/loxP mice (control) at 1 year of age (Fig 5b). More 





of the enlarged parallel fibers in the cerebellar molecular layer by wildtype oligodendrocytes, 
as indicated by Gallyas silver impregnation (Gallyas, 1979) (Fig. 5c). 
 
 
Fig. 5. Genetic loss of Pten in cerebellar granule cells triggers de novo myelination by 
progressive enlargement of granule cells and parallel fibers. (a) Immunostaining for GABAA 
receptor 6 subunit (in red), a cerebellar GC marker, at 1 year. Increased cell size in the mutants is 
indicated by dashed lines. (b) Progressive enlargement of Pf calibers in the mutant molecular layer 
(ML) over time as determined by EM (n=3 per genotype and age, 140 Pf quantified per animal). (c) 
De novo myelination of normally unsheathed parallel fibers in the cerebellum. In comparison to 
control brains (left), without myelin in the molecular layer (ML), Gallyas silver impregnation (Gallyas, 
1979) of myelin demonstrates the presence of robust levels of ectopic myelin in the molecular layer 





2.7 Aim of the study 
In the vertebrate nervous system, myelin decreases the electrical capacity of axonal 
membranes and enables rapid salutatory impulse propagation. The failure of 
oligodendrocytes and Schwann cells to achieve normal myelination causes severe 
neurological diseases, including leukodystrophies and peripheral neuropathies (Boespflug-
Tanguy et al., 2008; Suter and Scherer, 2003). Moreover, in myelin diseases such as 
multiple sclerosis (MS), the remyelination of axons is often inefficient. This leads to axonal 
degeneration and persistent clinical disability (Franklin and Ffrench-Constant, 2008). Thus, 
it is of major importance to develop therapies that stimulate rapid and efficient myelin repair 
by oligodendrocytes. The finding that the number of oligodendrocyte precursor cells (OPCs) 
found in MS plaques is apparently not the limiting problem of remyelination (Bauer et al., 
2012; Franklin and Ffrench-Constant, 2008), accentuates the need for a precise 
identification of signals that might stimulate OPCs differentiation and myelination in vivo. 
Thus the aim of the study is to understand how OPC proliferation, differentiation and 
myelination in the developing and adult brain is controlled and in what way axon-derived 







3.1 Pten mutant GC trigger de novo myelination of Pf axons 
Cell size is regulated by the Akt/mTOR pathway, which itself is stimulated by 
phosphatidylinositol-3,4,5-trisphosphate [PI(3,4,5)P3] (Laplante and Sabatini, 2012) (Fig. 
6a). Loss of the lipid phosphatase PTEN can therefore increase cell size (Stiles et al., 
2004a). To specifically enlarge cerebellar granule cells (GC) and their axonal projections 
(Pf), we deleted Pten in a novel line of Tg(m6)-Cre*PtenloxP/loxP mice that express Cre under 
control of the GABAA receptor 6 subunit promoter (Funfschilling and Reichardt, 2002; 
Lesche et al., 2002). As demonstrated by reporter gene expression in Tg(m6)-Cre mice, 
recombination starts at around P9 in predominantly postmitotic and postmigratory GC 
(Funfschilling and Reichardt, 2002). By quantitative RT-PCR and Western blot analyses the 
cerebellum of Tg(m6)-Cre*PtenloxP/loxP mice (hereafter termed Pten cKO or “mutants”) 
revealed a significant loss of Pten mRNA (by 63%) (Fig. 6b) when compared to PtenloxP/loxP 
mice (hereafter termed “controls”). To determine if indeed expression of PTEN was 
disrupted in Pten mutant mice, immunoblot analysis with antibodies specific for PTEN was 
performed using cerebellar lysates of control and mutant mice at the age of 3.5 months. 
The protein abundance of PTEN was reduced by 80% (p=0.0025) in Pten cKo (Fig. 6c). 
Loss of PTEN resulted in enhanced phosphorylation of AKT, GSK3β, mTor and S6 (Fig. 








Pten mutant mice were born in the expected Mendelian ratio and appeared healthy during 
the first months of life (Video 1, can be found on the included CD-ROM or on Nature 
Neuroscience webpage http://www.nature.com/neuro/journal/vaop/ncurrent/fig_tab/nn. 
4425_SV1.html). During postnatal development the cerebellum of Pten mutant mice 
became progressively enlarged (Fig. 7a). Hematoxylin and eosin staining (H&E) of 
parasagittal sections at P14 revealed no detectable difference between control and mutant 
mice, whereas at 2.5 months of age the size increase became obvious and revealed to be 
progressive, when analyzed at 1 year of age. The diameter of parallel fibers in the ML, next 
to bigger granule cells immunostained for GABAA receptor 6 subunit (Fig. 5a) also 
increased over time, as quantified by electron microscopy, reaching 0.61±0.009 µm in 




Fig. 6. Pten mutant granule cells stimulate the AKT1/mTOR pathway. (a) Schematic 
representation of selected candidates of PI3K/AKT1/mTORC1 signaling. (b) By qRT-PCR Pten 
transcripts containing the floxed exon 5 are decreased in the cerebellum of conditional Pten mutants 
(age 3.5 months). Means ± s.e.m. n=5 mice each genotype (p=0.0231, two-tailed unpaired Student’s 
t-test). (c) On Western blots PTEN levels are decreased in the cerebellum of mutants (age 3.5 
months, cropped blot images). (d) Phosphorylation (p-) of the PI3K downstream effectors AKT1, 
GSK3, mTOR and S6 is enhanced in Pten mutant mice (age 3.5 months, cropped blot images).  
Fig. 7. Progressive enlargement of 
Pten mutant cerebella and 
increase in Pf diameter. (a) 
Conditional ablation of Pten in early 
postnatal GC causes progressive 
cerebellar enlargement as visualized 
by H&E staining (ages are indicated). 
Images are representative of 3 
similar experiments. (b) Pf have 
increased in diameter when 






To determine, whether ablation of Pten from cerebellar granule cells and the subsequent 
increase in their axonal diameter was sufficient to induce myelination of parallel fibers in the 
molecular layer, immunohistochemistry with antibodies directed against CNP and 
Parvalbumin was performed using parasagittal sections of control and mutant mice at the 
age of 1 year. Interestingly and in contrast to controls, chromogenic staining for CNP 
Fig. 8. Genetic loss of Pten triggers de novo myelination of parallel fibers. (a) Hematoxylin and 
CNP immunhistochemistry on sagittal cerebellar sections of 3.5 month old animals revealed de novo 
myelination of normally non-myelinated parallel fibers in the cerebellum. In comparison to control 
brains (top), without myelin in the molecular layer (ML), immunohistochemistry specific for CNP 
demonstrates the presence of robust levels of ectopic myelin in the molecular layer (ML) of mutant 
mice (bottom). (b) Myelinated parallel fibers in mutant brains (right) immunostained for CNP (green). 
Both Purkinje cells (PC) and molecular layer interneurons (IN) are Parvalbumin (red) positive (age 1 
year). Note the absence of myelin in the molecular layer (ML) of control brains (left). Arrowhead 






demonstrated a massive accumulation of myelin in the molecular layer of Pten mutant mice 
(Fig. 8a). By fluorescent double immunohistochemistry for CNP and Parvalbumin, a marker 
of Purkinje cells and ML interneurons, this finding of de novo myelination of parallel fibers 
(Fig. 8b) was validated. Beginning at P40 the number of mutant parallel fibers that became 
myelinated (labeled by immunostaining of CNP) progressively increased over time (Fig. 9). 
 
 
Fig. 9. Progressive de novo myelination of Pten mutant parallel fibers. In comparison to control 
brains, without myelin in the molecular layer (ML), immunostaining of myelin protein CNP (green) 
demonstrates the presence of robust levels of ectopic myelin in the molecular layer of mutant mice. 
Myelination increases significantly over time. PL, Purkinje cell layer; GL, granule cell layer; ML, 
molecular layer.  
 
To illustrate newly formed myelin on a single cell level and to analyze how de novo 
myelination affected Pf morphology, we performed electron microscopic analyses of 1 year 
old Pten mutant mice. Indeed also by EM we could identify de novo myelinated Pf (marked 
by asterisks) that were presumably ensheathed by the depicted oligodendrocyte in close 
proximity (Fig. 10a). Myelination of parallel fibers induced the ectopic formation of node-like 
structures on Pf that were flanked by paranodal myelin loops (Pn). Furthermore EM analysis 
revealed the formation of septate-like junctions of the inner myelin leaflet with the Pf 
membrane (Fig. 10b). EM images of myelinated Pf axons also demonstrated that the newly 





these synapses to reside in the newly established nodal regions. These "en passant" 
synapses harbored presynaptic vesicles (arrowhead) (Fig. 11). 
 
Fig. 10. De novo myelination of parallel fibers and formation of node-like structures. (a) By 
electron microscopy (EM) normally unmyelinated parallel fibers (Pf) become de novo myelinated in 
mutant mice. Asterisks mark myelinated Pf (age, 1 year). Note the formation of a node of Ranvier 
(N), flanked by paranodal (Pn) loops (in b, black arrows).  
 
By EM analysis the amount of newly formed myelin in Pten mutants was measured by 
dividing the inner myelin diameter by the outer myelin diameter (g-ratio, Fig. 12a). The g-
ratio was plotted against the axonal caliber. Note that a g-ratio of 1 denotes an unmyelinated 
axon. An electron micrograph in Fig. 12b shows one of the smallest detected myelinated 
parallel fiber and by subsequent analyses we determined a size threshold for myelination 
in the mutants of approx. 0.25 µm (Fig. 12c). By morphometry and g-ratio analysis of 
controls and mutants, up to 403% of Pf in the ML were myelinated at 1 year of age. At that 
age, mutant Pf exhibited an average g-ratio of 0.84. The first myelinated parallel fibers 
appeared at the age of P40 (2.30.6%). Further analysis at 3.5 months revealed up to 
9.51% myelinated parallel fibers (Fig. 12c). At all analyzed ages, axons larger than 0.45 






Fig. 11. Parallel fiber synapses onto Purkinje cell dendritic spines in the presence of myelin. 
EM images of de novo myelinated Pf in mutants at 1 year of age. The “en passant” synapses of Pf 
on Purkinje cells spines appeared restricted to the newly established nodal regions. Arrowheads 






Fig. 12. G-ratio analysis. (a) The amount of myelin was measured by dividing the inner myelin 
diameter by the outer myelin diameter. (b) By EM, de novo myelination of mutant Pf requires a 
minimum axonal caliber of 0.25 µm. We never observed thinner myelinated axons than the one 
shown (age 1 year). (c) Progressive myelination as quantified by g-ratio analysis of myelin thickness 
at the indicated ages. Note that a g-ratio of 1 denotes for unmyelinated axons. There is continuous 
increase in the number of myelinated fibers in mutants (red dots). In controls (blue dots) myelin 
profiles are virtually absent (n=3 per genotype and age, 140 Pf quantified per animal). 
 
Taken together, activation of the PI3K/AKT/mTOR pathway in cerebellar granule cell 
neurons of conditional Pten mutant mice was sufficient to induce a granule cell hypertrophy, 
a thickening of their associated axons and a progressive de novo myelination of the normally 






3.2 Pten mutant GC trigger OPC proliferation and differentiation 
The ML harbors normally hardly any oligodendrocytes and only scattered NG2 positive 
cells, as demonstrated in Plp1-DsRed*Ng2-EYFP double-transgenic mice (Hirrlinger et al., 
2005; Karram et al., 2008) (Fig. 13a). Immunohistochemistry with an antibody directed 
against carbonic anhydrase (CAII), a marker of mature oligodendrocytes, revealed 
significantly more oligodendrocytes in the GL (+33%) and ML (+750%) of Pten mutants. 
Unaltered numbers of CAII positive cells were detected in the WM of Pten mutants as 
compared to controls, when quantified at P45 (Fig. 13b). 
 
 
Fig. 13. Local differentiation of OPCs induced by de novo myelination. (a) The normal cerebellar 
ML is devoid of oligodendrocytes (red), but contains scattered NG2+ OPCs (green), as revealed by 
DsRed and EYFP fluorescence, respectively, in double-transgenic Plp1-DsRed*Ng2-EYFP mice. 
The depicted picture was kindly provided by Dr. Khalad Karram from the Institute for Molecular 
Medicine, Mainz, Germany. GL, granule cell layer; ML, molecular layer. (b) Mature oligodendrocytes 
(carbonic anhydrase/CAII-positive) are more numerous in the mutant granule cell layer (p=0.0498) 
and molecular layer (p=0.0103), but not in cerebellar white matter (WM; p=0.8581). All analyses at 
age P45 (n=3 per genotype). Data are means ± s.e.m. *p<0.05, student’s t test. GL, granular cell 
layer; ML, molecular layer; WM, white matter. 
 
To determine whether Pten deficient axons induce OPC proliferation within the ML or 
whether OPCs are recruited from the GL below, we used 5'-bromo-2'-deoxyuridine (BrdU) 
labeling detection, in combination with antibodies directed against specific oligodendroglial 
marker antigens (Fig. 14a). BrdU is a thymidine analog that incorporates into dividing cells 
during DNA synthesis (Wojtowicz and Kee, 2006). Once it is incorporated into the new DNA, 
BrdU will remain in place and will be passed down to daughter cells following division 





Fig. 14. Local proliferation of OPCs in the molecular layer. (a) In the cerebellar ML of Pten mutant 
mice, many OPCs (Olig2+, red) nuclei can be co-labeled for BrdU (green, arrowheads), following 
daily BrdU administration between P25-P45. (b) At age P45, the density of proliferating OPC 
(BrdU+;Olig2+) is only increased in the ML (n=3 per genotype; p=0.0004), but proliferation remains 
elevated at age P201 (n=3 per genotype; p=0.0016). Thus, by P201 the total number of Olig2+ 
oligodendrocyte lineage cells in the ML is 10-fold higher than in controls (n=3 per genotype; 
p=0.0031). (c) After daily BrdU injections (between P25 and P45) newly generated OPC of the ML 
also turn into mature oligodendrocytes, as revealed by quantifying cells that are co-labelled for BrdU 
(green) and CAII (red). N=3 per genotype (p=0.0006). (d) By chromogenic in situ hybridization, Myrf 
mRNA can be detected in single differentiating oligodendrocytes of the mutant ML (arrowheads in 
middle panel), suggesting ongoing differentiation. Myrf+ differentiating OL were never detected in 
the control ML. Right: section from a developmental stage (P20) as a positive control for Myrf 





We injected BrdU intraperitoneally (i.p.) from P25-P45, if not mentioned otherwise. When 
the number of BrdU+;Olig2+ cells was analyzed at P45 (i.e. after 20 days of daily BrdU 
injection) and compared between mutants and controls, OPC proliferation was not 
significantly different in the GL and the WM of mutant mice (Fig. 14b). However, in the ML 
BrdU+;Olig2+ cells were 4.4-fold increased (Fig. 14b). Even at 6-7 months, the 20-day BrdU 
treatment protocol (i.p. injection of BrdU from P181-P201) revealed a 4.7-fold increase of 
BrdU+;Olig2+ cells in the mutant ML (Fig. 14b). At that age the total number of 
oligodendrocyte lineage cells had reached a 10-fold increase compared to controls (Fig. 
14b). Importantly, double-labeling of BrdU and CAII confirmed that newly generated OPCs 
that had incorporated BrdU during the 20 day period of BrdU injection, differentiated into 
CaII expressing mature oligodendrocytes (Fig. 14c). In a collaboration with Kuo Yan at the 
Institute of Cell Biology and Neurobiology, Berlin (Germany), we performed a chromogenic 
in situ hybridization for Myrf mRNA on parasagittal sections of the cerebellum. Myrf (Myelin 
Regulatory Factor) is a membrane-associated transcription factor and is required for the 
generation of CNS myelin during development (Bujalka et al., 2013). Myrf is required for the 
final stages of oligodendrocyte differentiations and is expressed exclusively by maturating 
oligodendrocytes. In fully mature oligodendrocytes Myrf is almost undetectable (personal 
communication with Ben Emery, Jungers Center for Neurosciences Research, Department 
of Neurology, Oregon USA). With this in situ hybridization we could confirm that even at 7 
months of age the ML in mutant brains still contained some maturating oligodendrocytes 
(Fig. 14d). As a positive control for Myrf expression we used parasagittal cerebellar sections 
of a P20 wild type mouse.  
To better define the timing of OPC proliferation in Pten deficient mice, we injected BrdU 
from P15-P20 and quantified BrdU+,Olig2+ cells in the ML of control and mutant mice. At 
P20 there was no detectable difference in the number of double positive cells (Fig. 15a). 
Using a slightly later BrdU injection protocol (P20-P30) we identified a time window at which 
proliferation of OPCs was already increased but the number of mature (CNP+) 
oligodendrocytes was not (Fig. 15b). This indicates that OPC proliferation is independently 
activated by the genetically modified granule cells and not just a mere homeostatic 
mechanism to replace OPCs that have matured to the myelinating state. This result was 
validated by immunohistochemical analysis at P45 (and after BrdU administration between 
P25-P45) with antibodies directed against MBP and BrdU. Here, we found that BrdU labeled 
OPCs were uniformly distributed over the mutant ML and not in close proximity to mature 






Fig. 15. Early onset of proliferation (a) The number of proliferating OPCs (BrdU+Olig2+) in the ML 
following daily BrdU administration from P15 to P20 is similar in mutants and controls (p=0.3161). 
(b) In contrast, after daily BrdU administration between P20 and P30 (analyzed at P30) the number 
of proliferating OPCs (BrdU+,Olig2+) in the ML is increased in the mutants (p=0.0120). However, at 
that age, the number of mature oligodendrocytes expressing CNP is unchanged between control and 
mutants (p=0,8025), indicating that proliferation of OPCs proceeds the differentiation of OPCs to 
oligodendrocytes. (c) OPCs labeled for BrdU (asterisks) distribute evenly in the ML of Pten mutants 
and are not preferentially close to newly generated oligodendrocytes and their myelin sheaths 
(arrowheads). N=3 per genotype, Data are means ± s.e.m. *p<0.05, student’s t test. 
 
Taken together, the inactivation of Pten in cerebellar granule cells increased Pf caliber 
above a "threshold" of 0.25 µm and was sufficient to induce OPC proliferation, OPC 










3.3 Is ectopic myelination triggered by neuronal activity? 
Proliferation of OPCs and myelination in the CNS can be triggered by neuronal activity 
(Gibson et al., 2014; Li et al., 2010). OPCs receive synaptic input from Pf in the cerebellar 
ML (Lin and Bergles, 2004) and altered synaptic input modulates OPC proliferation (Mangin 
et al., 2012) and myelination (Wake et al., 2011). To test the hypothesis if the de novo 
myelination upon Pten deficiency in granular cells is triggered by neuronal activity, we 
started a collaboration with Sonia Spitzer and Ragnhildur Thóra Káradóttir from the 
University of Cambridge, UK. Here, Pten mutants were tested for altered Pf electric activity 
picked up by OPCs in the ML. Using acute slices from mutant and control mice that 
additionally expressed the Ng2-EYFP transgene (Karram et al., 2008), our colleagues 
whole-cell patch clamped both Purkinje cells, that receive input dominantly from Pf, and 
fluorescent OPCs in the ML. This allowed them to determine GC activity and the 
spontaneous synaptic inputs from the Pf to the OPCs. However, no differences were found 
between mutants and controls in the spontaneous postsynaptic inward currents recorded 
from NG2-EYFP expressing OPCs (Fig. 16a,b) nor in the frequency of the spontaneous 
synaptic input to the OPCs (Fig. 16c). Similar the frequency of spontaneous inputs to 
Purkinje cells showed no significant difference (Fig. 16d). Taken together, the data of our 
collaborators suggest that de novo myelination of parallel fibers in young Pten mutants is 
not triggered by neuronal activity. 
 
Fig. 16. Ectopic 
myelination is not 
triggered by neuronal 
activity. (a) Spontaneous 
postsynaptic inward 
currents recorded from 
NG2-EYFP expressing 
OPCs clamped at -74mV in 
the ML of control and Pten 
mutant mice. (b) Inward 
currents appeared at an 
expanded time scale. (c) 
The average frequency of 
detectable spontaneous 
events in OPCs is 
comparable between 
controls (n=5; 0.027x10-3 
Hz) and mutants (n=6; 
0.024x10-3 Hz) (p=0.94). (d) Similarly, there is no significant difference in the frequency of 
spontaneous inputs in Purkinje cells (PC), which are predominantly from Pf (control, n=5, 0.87x10-





3.4 Is ectopic myelination triggered by down regulation of inhibitory cues? 
Some reports in the literature suggest that axon–bound signaling proteins are not essential 
for regulation of CNS myelination. For example, it has been reported that oligodendrocytes 
can ensheath synthetic nanofibers in vitro (Lee et al., 2012). Hence, we hypothesized that 
(i) axons have to meet a 0.25 µm “size threshold” to become myelinated (Lee et al., 2012), 
and that (ii) oligodendrocytes respond with myelination to instructive diffusible factors or to 
the down regulation of inhibitory cues that could be axon-bound or diffusible.  
To test for possible inhibitory axonal cues, we intercrossed floxed Pten mutants (Lesche et 
al., 2002) to a Nex-CreERT2 driver line (Agarwal et al., 2012). In contrast to Tg(m6)-Cre 
mice (which recombine more than 90% of cerebellar granule cells) the Nex gene promoter 
targets Cre only in a minor fraction of all granule cells (Agarwal et al., 2012). Indeed, after 
5 consecutive days of tamoxifen treatment (P10-P15), reporter gene expression was 
detectable in less than 4% of all cerebellar granule cells (Fig. 17a). However, when 
analyzed 28 weeks later (Fig. 17b), loss of PTEN in this small fraction of granule cells was 
sufficient to significantly increase the number of mature oligodendrocytes, expressing CNP 
(Fig. 17c,d). Importantly, these mature oligodendrocytes, similar to our previous findings in 
Tg(m6)-Cre*PtenloxP/loxP mice, participated in de novo myelination of parallel fibers. 
Accordingly, a significantly larger MBP positive area could be quantified in Nex-
CreERT2*PtenloxP/loxP mutants compered to age matched controls (Fig. 17e,f).  
Since 96% of the Pf were non-recombined in Nex-CreERT2*PtenloxP/loxP mice and thus 
wildtype with regard to the expression of potential inhibitory, diffusible cues, our data 
strongly suggests that the induction of de novo myelination of parallel fibers is unlikely 







Fig.17. Cell type specific ablation of Pten in a small subset of cerebellar granule cells. (a) 
Tamoxifen treatment of Nex-CreERT2*Rosa26-lacZ mutant mice induces Cre-mediated activation of 
a lacZ reporter gene in a small subset of GC. (b) Tamoxifen treatment scheme for Nex-
CreERT2*PtenloxP/loxP mutant mice. (c,d) Nex-CreERT2*PtenloxP/loxP mutants harbor significantly more 
CNP positive oligodendrocytes (arrowheads) in the ML, when compared to controls. (e,f) Targeted 
ablation of Pten by Nex-CreERT2 induced a significantly larger MBP positive area in the ML when 
compared to controls (quantitated in parasagittal sections of the cerebellar vermis; n=3 per genotype 
and indicated age). Data are means ± s.e.m. **p<0.01; ***p<0.001, student’s t test (d,f). GL, granule 










3.5 Functional validation of selected candidate factors 
3.5.1 Experimental design and hypothesis 
Pten deficient mice and their controls were further used as a tool, helping to find 
promyelinating factors in the CNS. We used laser captured microdissection and obtained 
stripes of the GL from cerebellar cryosections of 3.5 month-old mutants and age-matched 
controls (Fig. 18a). We isolated RNA for global transcriptome analyses using microarrays 
(Affymetrix Mouse Genome 430A 2.0 Array). Transcriptome analysis resulted in a first list 
of candidate factors upregulated in Pten cKO (Fig. 18b). Candidate transcripts were 
selected by several criteria, including magnitude of upregulation in the transcriptome of Pten 
mutant GL vs. control GL (>1.4 fold, n=3 per genotype), level of significance (p<0.05) and 
annotation. The resulting candidate list included e.g. neurotensin (Nts; 32.8-fold), inhibin 
beta-A (Inhba, forming the biologically active dimer Activin A; 4.4-fold), thymosin beta 4 
(Tmsb4x, 2.4-fold), tissue inhibitor of metalloproteinase 3 (Timp3, 2.1-fold), secreted 
protein, acidic and rich in cysteins-like 1 (Sparcl1, 1.9-fold), vascular endothelial growth 
factor c (Vegfc, 1.9-fold), fibroblast growth factor 1 (Fgf1, 1.6-fold), pleiotrophin (Ptn or 
heparin-binding growth factor 8/Hbfg-8, 1.5-fold) and brain-derived neurotrophic factor 
(Bdnf, 1.4-fold). The database from http://web.stanford.edu/group/barres_lab/ 
brain_rnaseq.html (Zhang et al., 2014) was used to indicate which cell type showed the 
highest expression of the corresponding gene. For example, Nts is mainly expressed by 
neurons and endothelia cell; Inhba, by OPCs, neurons and astrocytes; Tmsb4x, by 
endothelia cells and microglia; Timp3, Sparcl1, FGF1 and Ptn, by astrocytes; Vegfc, by 
endothelia cells and Bdnf, by neurons and astrocytes (Zhang et al., 2014). To further 
validate the obtained transcriptome data, some differentially expressed candidate genes 
were further analyzed by qRT-PCR. Nts, FGF1, Ptn, Timp3 and Inhba showed a 
significantly higher mRNA abundance in cerebellar lysates from Pten cko compared to 







Fig.18. Experimental design to test candidate factors which were identified in conditional GC-
specific Pten mutant mice and may have an impact on oligodendrocyte development. (a) Laser 
capture microdissection (LCM) was used to obtain the granular cell layer from serial cerebellar 
sections at the age 3.5 months (representative section shown). (b) Candidate transcripts were 
selected by several criteria, including magnitude of upregulation in the transcriptome of Pten mutant 
GL vs. control GL (>1.4-fold, n=3 per genotype), level of significance (p<0.05) and annotation. The 
third column indicates the cell type with the highest expression of the corresponding gene, according 
to the database: http://web.stanford.edu/group/barres_lab/brain _rnaseq.html (Zhang et al., 2014). 
A, astrocyte; N, neuron; OPC, oligodendrocyte precursor cell; NFO, newly formed oligodendrocyte; 
MO, myelinating oligodendrocyte; M, microglia; E, endothelial cells; FC, fold change. (c) qRT-PCR 
analysis of mRNAs encoding for some differentially expressed candidate genes. Analyzing 
cerebellum lysates from Pten cko and control mice, revealed a significantly higher mRNA abundance 
of Nts, FGF1, Ptn, Timp3 and Inhba (age 3.5 months). Data are means ± s.e.m. *p<0.05; ***p<0.001, 





Some mRNAs encoded secreted proteins that had been associated with oligodendrocyte 
development before, at least in vitro, such as Bdnf (Xiao et al., 2010), Vegfc (Le Bras et al., 
2006), Ctgf (Stritt et al., 2009) and Tmsb4x (Santra et al., 2012). Other factors, including 
Fstl1, IGFBP-4, Dkk-3, Apcdd1, and Sfrp4, are new but known as antagonists of Wnt and 
Bmp signaling (Cruciat and Niehrs, 2013; Sylva et al., 2013), i.e. negative regulatory 
pathways of oligodendrocyte differentiation (He and Lu, 2013). Also modulators of insulin-
like growth factor (IGF) signaling (IGFBPs 2, 3, and 7), which is thought to play a role in 
oligodendrocyte development (Taveggia et al., 2010), were upregulated. Finally, the 
metallopeptidases MMP17 and Adamts1 showed enhanced expression. The latter is 
relevant for myelination, as these proteases serve functions in remodeling the extracellular 
matrix and in the degradation of those proteins (such as chondroitin sulfate proteoglycans) 
that inhibit remyelination (Lau et al., 2013). 
We hypothesized that de novo myelination of the cerebellar molecular layer in Pten mutant 
mice is initiated by a neuronal developmental program. The increase of axon size is 
PI3K/Akt/mTOR-dependent and associated with the upregulated expression of numerous 
genes, identified by transcriptional profiling of laser captured GC layers.  
 
3.5.2 In vivo uncoupling of brain derived neurotrophic factor (Bdnf) 
To address the significance of our candidate list, we selected Brain derived neurotrophic 
factor (Bdnf) for an in vivo analysis. Bdnf is a member of the nerve growth factor family 
(Levimontalcini and Angeletti, 1968) that supports existing neurons and influences growth 
and differentiation of new neurons and synapses (Acheson et al., 1995; Huang and 
Reichardt, 2001). The role of Bdnf and its receptor TrkB for oligodendroglia survival, 
differentiation, and myelination has been previously studied in vitro and in vivo. Till now no 
full picture about its functions has emerged yet, but Bdnf is thought to have a promyelinating 
effect (Xiao et al., 2010). 
Floxed Bdnf mice (Rauskolb et al., 2010) were kindly provided by Michael Sendtner 
(Institute for Clinical Neurobiology, University of Würzburg). We generated triple-mutant 
mice by Tg(m6)-Cre mediated targeting of Pten (for ectopic myelination) in combination 
with the floxed Bdnf gene. We hypothesized that if Bdnf is essential for myelination, its 
conditional inactivation in double mutant granule cells should result in reduced de novo 
myelination. 
Surprisingly, at both analyzed ages (7 and 10 weeks) Tg(m6)-Cre*PtenloxP/loxP*BdnfloxP/loxP 





significantly higher (not lower) number of mature (CNP+) oligodendrocytes in the ML than 
Pten single mutants (Pten cKO) (Fig. 19a,b). Also the (MBP+) myelinated area of the ML 
was significantly larger (not smaller), when quantified by immunostaining at the age of 7 
and 10 weeks (Fig. 19c,d). Interestingly, even Pten het*Bdnf cKO showed significantly 
more CNP+ oligodendrocytes at 7 weeks of age than control mice. This difference is 
undetectable at 10 weeks of age. 
 
 
Fig.19. Histological in vivo validation of Bdnf uncoupling. (a) CNP was labeled on cerebellum 
slices of 10 weeks old control Pten cKO and Pten*Bdnf double mutant mice. (b) Double mutants 
lacking both Pten and Bdnf in cerebellar granule cells harbour significantly more CNP positive 
oligodendrocytes, at both time points (7 weeks: p=0.0132, 10 weeks: p=0.0012). (c,d) 
Immunohistochemistry for MBP exhibited a larger MBP positive area (7 weeks: p=0.0024, 10 weeks: 
p=0.0476) in the ML of double mutants, when compared to single Pten mutants (quantitated in 
parasagittal sections of the cerebellar vermis; n=3-4 per genotype and indicated age). Data are 
means ± s.e.m. *p<0.05; **p<0.01; ***p<0.001, one-way analysis of variance (ANOVA) followed by 
Bonferroni test (b,d). GL, granule cell layer; ML, molecular layer. 
 
By electron microscopy we confirmed that the Pf calibers, independent from whether 
myelinated or unmyelinated, were as enlarged as in Pten single mutants (Fig. 20a). 
However, by g-ratio analysis at the age of 10 weeks the thickness of myelin was slightly but 
significantly reduced (indicated by a bigger g-ratio, p=0.0259) in Pten*Bdnf double mutants 







Fig. 20. Electron microscopy of Pten cKO and double mutants lacking Pten and Bdnf. (a) 
Caliber measurements of myelinated (p=0.4339) and unmyelinated (p=0.5558) Pf diameters 
demonstrated no detectable difference between single Pten mutants and double mutants lacking 
both Pten and Bdnf. (b,c) G-ratio analysis of ML myelin in Pten single mutants and Pten*Bdnf double 
mutants revealed a slightly reduced myelin sheath sickness (indicated by a bigger g-ratio, p=0.0259). 
Data are means ± s.e.m, *p<0.05, student’s t test, n=3 per genotype. 
 
Taken together, in the absence of Bdnf expression from Pten mutant granule cells, radial 
axonal growth was not altered, mature oligodendrocytes became more numerous and the 
observed ectopic myelin was thinner. Our data suggests that neuronally expressed Bdnf is 
as a coregulator of CNS myelination, which demonstrates the relevance of our experimental 
approach. Nevertheless, the double mutant phenotype was puzzling and had to be defined 
in more detail.  
 
As a working hypothesis we took into account that OPCs in Pten mutants receive both, "pro-
proliferation" and "pro-differentiation" signals and that the simultaneous reaction of an OPC 
to both conflicting stimuli is impossible. Assuming that Bdnf is one of the "pro-differentiation" 
signals for OPCs in the mutants, its loss in double mutants would increase the weight of the 
"pro-proliferative" signals and thereby increase the number of OPCs generated in the ML. 
However, at a later stage the remaining "pro-differentiation" factors would still suffice to 
trigger OPC differentiation and myelin sheath formation, possibly with some temporal delay. 
This would explain our seemingly paradoxic result of more ectopic myelin in the conditional 





To test this hypothesis, we determined OPC proliferation at the age of 7 weeks in conditional 
double mutants and in Pten single mutants that had received daily BrdU injections between 
P25 and P45 (Fig. 21a). Indeed, double mutants showed 34% more BrdU labeled Olig2+ 
OPCs in the ML than Pten single mutants (p=0.0426, n=4 per genotype) (Fig. 21b). We 
noted that a lack of Bdnf also induced a higher proliferation of OPCs in heterozygous Pten 
mutants when compared to controls. This suggested a role of Bdnf to control the number of 




Fig. 21. Increased local proliferation of OPCs in double mutants lacking Pten and Bdnf. (a) 
BrdU was administered by intraperitoneal (i.p.) injection from P25-P45 and histology was performed 
4 days later. Double positive cells are labelled with an arrowhead. (b) Quantitation of BrdU positive 
Olig2 expressing cells in the ML of parasagittal sections of the cerebellar vermis revealed significantly 
more double positive cell in Pten cKO*Bdnf cKO mice compared to single Pten mutants (n=3-4 per 
genotype, p=0.0426). Data are means ± s.e.m. *p<0.05; ***p<0.001, one-way analysis of variance 
(ANOVA) followed by Bonferroni test. ML, molecular layer; GL, granule cell layer; WM, white matter. 
 
3.5.3 In vivo uncoupling of Neuregulin 1 (Nrg1) 
Nrg1 is another interesting axonal grow factor, since it is essential for myelination by 
Schwann cells in the PNS. As detailed in the introduction, its role in CNS myelination is still 
under debate. As a second in vivo uncoupling experiment we generated Tg(m6)-
Cre*PtenloxP/loxP*Nrg1loxP/loxP double mutant mice (hereafter termed Pten cKO*Nrg1 cKO). 
When compared to Pten single mutants at 10 weeks of age we found no difference in the 
number of (CNP+) oligodendrocyte (Fig. 22a). Analysis of MBP+ area also revealed no 
significant differences between single Pten mutants and Pten cKO*Nrg1 cKO (Fig. 22b). 
Additionally, g-ratio analysis and quantification of Pf calibers (myelinated and unmyelinated 
fibers) on electron microscopic sections at the age of 10 weeks showed no detectable 






Fig. 22. Neuregulin 1 is not required for Pf myelination in Pten mutant mice. (a) Double mutants 
lacking both Pten and Nrg1 in cerebellar granule cells (Pten cKO*Nrg1 cKO) do not differ from single 
Pten mutants (Pten cKO), when comparing oligodendrocyte numbers in the ML (CNP positive cells, 
p=0.1068). (b) Quantification of MBP+ area revealed no difference between single Pten mutants and 
double mutants lacking Pten and Nrg1 (p=0.0982). Quantified were parasagittal sections of the 
cerebellar vermis (n=3-4 per genotype; 10 weeks of age). (c,d) G-ratio analysis derived from 
electronmicrographs of Pten cKO and Pten cKO*Nrg1 cKO mutants showed no significant difference 
(n=3 mice each genotype; 10 weeks of age; p=0.0581). (e) Caliber measurements of myelinated and 
unmyelinated Pf revealed no significant difference (n=3 per genotype; 10 weeks of age). Data are 
means ± s.e.m. ***p<0.001, student’s t test (d,e) or one-way analysis of variance (ANOVA) followed 






3.5.4 In vitro validation of selected candidate factors 
Because of the complexity of myelination control in vivo, we turned to simpler assay systems 
for proof-of-principle and to assess if our selected candidates indeed affect the fate of OPCs 
and oligodendrocytes. We used either mixed primary oligodendrocyte cultures (devoid of 
axons) from spinal cord of 4 day-old mouse pups or neuron-glia cocultures (that myelinate 
in vitro) prepared from E13 mouse spinal cord. Recombinant candidate proteins (chosen by 
diffusibility of the encoded protein, extent of upregulation, annotation, and overall 
plausibility) were added to the media at either 10 ng/ml (Sparcl1, Ptn) or 100 ng/ml (all other 
factors). After 3 and 5 days OPCs and oligodendrocytes in mixed cultures were quantified 
with antibodies against Olig2 (a pan-OL lineage marker) and the Adenomatosis polyposis 
coli (Apc) gene product (clone APC-CC1), a marker of postmitotic oligodendrocytes. 
Numbers and proliferation of oligodendrocyte lineage cells as well as in vitro myelination in 
neuron-glia cocultures were scored after 25 days by using antibodies against Olig2, Ki67 (a 
proliferation marker), MBP, and phosphorylated neurofilament as an axonal marker antigen 
(SMI31). In these experiments, our selected factors triggered different responses in 
oligodendrocyte lineage cells. 
 
3.5.4.1 Proliferation assay 
OPC proliferation was induced by adding recombinant acidic Fgf1 to myelinating cocultures. 
(Fig. 23a,b). The numerical increase in OPCs correlated with a 1.5-fold higher number of 
Ki67 positive Olig2+ cells (Fig. 23c,d). Other factors tested (including Sparcl1, Vegfc, 
Pleiotrophin, Tmsb4x, Timp3 and Activin A) showed no pro-proliferative effect. The OPC-
mitogen Pdgf served as a positive control and significantly increased the relative percentage 








3.5.4.2 Differentiation assay 
When determining the fraction of OPCs in primary mixed cultures (Fig. 24a) that had turned 
into mature postmitotic (APC/CC1+) oligodendrocytes after 3 (or 5) days of treatment, this 
number was significantly increased when Activin A was added (Fig. 24b). However, none 
of the other factors tested including Klotho (400ng/ml), which enhanced OPC maturation of 




Fig. 24. Differentiation assay. (a) Representative images of a mixed primary oligodendrocyte cultures, 
co-immunostained for GFAP and MBP (left) or Olig2 and Apc-CC1 (right) after 3 days in culture. (b) 
Quantitation of the percentage of CC1 expressing cells in relation to Olig2 positive cells after 3 and 
5 days treatment with either vehicle or one of the indicated recombinant proteins (n=3-5 for both time 
points). Klotho was included as a positive control (Chen et al., 2013), although the addition showed 
no significant effect (3 days: Vehicle vs. Klotho, p=0.5403; 5 days: Vehicle vs. Klotho, p=0.6483). 
Adding the recombinant form of Activin A to the mixed primary oligodendrocyte cultures increased 
(both time points) significantly the percentage of CC1 expressing cells in relation to Olig2 positive 
cells (3 days: Vehicle vs. Activin A, p=0.0003; 5 days: Vehicle vs. Activin A, p=0.0026). Pleiotrophin 
and Timp3 showed no such effect (3 days: Vehicle vs. Pleiotrophn, p=0.2397, Vehicle vs. Timp3, 
p=0.5629; 5 days: Vehicle vs. Pleiotrophin, p=0.8878, Vehicle vs. Timp3, p=0.7308). Data are means 
± s.e.m. **p<0.01; ***p<0.001, Wilcoxon matched pairs test. 
 
 
Fig. 23. Proliferation assay. (a) Representative images of cocultures treated with recombinant 
proteins and immunostained for Olig2 (pseudocolored in green) 13 days later. Cell nuclei are 
counterstained with DAPI (pseudocolored in red). (b) Quantitation of Olig2 positive cells after 
treatment of cocultures with the indicated selected factors between 12 and 25 days in vitro (DVI). 
The relative percentage of Olig2 positive cells was calculated by dividing the number of Olig2+ cells 
by the total cell number (determined by DAPI) and by normalization to vehicle treated cultures that 
were set to 100% (dashed line). The OPC-mitogen Pdgf served as positive control (n=3-4 
independent experiments, Pdgf: p=0.0113; Sparcl1: p=0.9947; Vegfc: p=0.3451; Fgf1: p=0.0179; 
Pleiotrophin: p=0.4774; Tmsb4x: p=0.3125; Timp3: p=0.1766; Activin A: p=0.0869). Treating 
cocultures with the recombinant form of Fgf1 increased the number of Olig2+ cells. (c) 
Representative images of cocultures treated with vehicle (top) or Fgf1 (bottom) and costained for 
Olig2 (pseudocolored in red) and Ki67 (pseudocolored in green). (d) Addition of Fgf1 to the coculture 
increased the percentage of Ki67 positive Olig2+ cells (n=4 independent experiments, p=0.0153). 





3.5.4.3 Myelination assay 
Finally, in neuron-oligodendrocyte cocultures (Fig. 25a) we studied whether any of the 
recombinant proteins promoted terminal oligodendrocyte differentiation and myelin sheath 
formation by quantifying (for each culture) the myelin-representing (MBP+) territory relative 
to the size of the underlying axonal (SMI31+) network. Using this system, several of our 
candidates, including Pleiotrophin, Tmsb4x, Timp3 and Activin A significantly increased the 
myelinated area, and emerged as novel pro-myelinating factors (Fig. 25b). We note that 
Fgf1 increased both Olig2 cell numbers and myelinated area (Fig. 23b, Fig. 25b). However, 
and in contrast to the other factors tested, we scored many more MBP+ flat membrane 
sheaths instead of compacted myelin wraps (Fig. 26). Both enhanced cell number and flat 
membrane sheaths distorted the true “pro-myelinating” effect, when analyzed by an 
automated ImageJ plug in. 
 
 
Fig. 25. Myelination assay. (a) Representative image of a myelinating coculture 
(neuron/oligodendrocyte, 25 days in vitro) immunostained for MBP and Smi31. (b) The “myelination 
index” was calculated by dividing the MBP positive area by the Smi31 positive area and defining this 
ratio as 1 in vehicle treated controls (dashed line) (n=3 for Vegfc, n=6 for Sparcl1 and Fgf1, n=11 for 
Pdgf, Ptn, Timp3 and Activin A). 5 added factors in this assay showed a singnificantly increased pro-
myelinatin activity (Fgf1: p=0.0498, Pleiotrohin: p=0.0005, Tmsb4x: p=0.025, Timp3: p=0.0264 and 
Activin A: p=0.0132). Adding the recombinant form of Pdgf, as a known “pro-proliferative" signal 
significantly reduced the calculated myelination index (Pdgf: p=0.0049). Sparcl1 and Vegfc showed 
no effect (Vegfc: p=0.8806, Sparcl1: p=0.5781). (c) Mixed primary oligodendrocyte cultures treated 
for 3 days with Activin A in combination with either 2.5 µM SIS3 (SI), 0.5 µM LY294002 (LY) or 10 
µM UO126 (UO) were co-immunostained for Olig2 and Apc-CC1. Quantification (n=3) of the 
percentage of CC1 expressing cells in relation to Olig2 positive cells after 3 days of treatment, 
revealed a significant abolishment of the Activin A effect by the specific inhibitor UO (Activin A vs. 
Activin A+UO: p=0.0005). SI and LY showed no significant reduction (Activin A vs. Activin A+SI: 
p=0.3050; Activin A vs. Activin A+LY: p=0.9959). Data are means ± s.e.m. *p<0.05; **p<0.01; 
***p<0.001, Wilcoxon matched pairs test (b), or one-way analysis of variance (ANOVA) followed by 







Fig. 26. Fgf1 treatment of myelinating cocultures favors “myelin-like” flat sheaths over 
compacted myelin wraps. Representative images of a myelinating coculture treated with Fgf1 
between DIV 12 and DIV 25 in culture and immunostained for MBP and Smi31. Compare to Fig. 
25a. 
 
 All in vitro studies described, were not optimized for any factor nor designed to characterize 
their function, but they provide “proof-of-principle” for the validity of a genetic approach that 
used ectopic myelination in vivo as its readout. However, for Activin A we used mixed 
primary oligodendrocyte cultures, to gain additional mechanistic insight (Fig. 24a). The 
TGF-like glycoprotein signals via type I and type II receptor serine/threonine kinases and 
the downstream transcription factors Smad2 and Smad3 (Tsuchida et al., 2009). 
Additionally, Smad-independent Activin A signaling involving p38 MAPK, ERK1/2, and AKT 
has been reported (Do et al., 2008; Tsuchida et al., 2009), i.e. pathways independently 
implicated in myelination control (Flores et al., 2008; Goebbels et al., 2010; Ishibashi et al., 
2006). To determine which downstream mechanism is most critical, we treated mixed 
primary OL cultures with recombinant Activin A in the presence or absence of different 
inhibitors. Inhibition of MEK1/2 with UO126 (UO) completely abolished the pro-
differentiation effect of Activin A, whereas inhibition of PI3K with LY294002 (LY) or inhibition 






3.5.5 The cell type specific origin of selected candidate factors 
Based on our experimental approach, we have no formal proof, that the cellular origin of the 
newly identified “differentiation/myelination factors" is neuronal. Indeed, by our 
transcriptome analysis of Pten cKO mutants and controls we identified several upregulated 
immune modulatory factors, e.g. Nts (neurotensin) and Ninj1 (Fig. 18b) with a role in 
immune cell migration (Ifergan et al., 2011; Katsanos et al., 2008). However, general 
microglia and macrophage marker antigens, including Aif1/Iba1 (allograft inflammatory 
factor 1/ionized calcium-binding adapter molecule 1), Cd68 (cluster of differentiation 68), or 
Itgam/CD11B (Integrin alpha M/cluster of differentiation 11B) were not differentially 
regulated (Fig. 27a). This is in line with immunohistochemical analysis of microglial marker 
antigens (Iba1, Mac-3) in the GL of Pten cKO (Fig. 27b). Similar, the quantification revealed 
no difference in cell numbers, between mutants and controls at the age of 2.5 month (Fig. 
27b,c). Nevertheless, Cd163 (Cluster of differentiation 163), which is considered a marker 
of anti-inflammatory or immunoregulatory M2 (alternatively activated) 
microglia/macrophages was 7-fold upregulated at the RNA level in the mutant GL (Fig. 
27a). Interestingly, M2 microglia and macrophage derived Activin A has recently been 
reported to drive oligodendrocyte differentiation (Miron et al., 2013). Additionally, moderate 
changes of Iba1 and Mac-3 positive cells could be identified in the ML of Pten cKO (Fig. 
27b,c). Quantification of GFAP+ area revealed the similar results (Fig. 27d). Furthermore, 
by immunohistochemistry for CD31 (cluster of differentiation 31/ PECAM-1, platelet 
endothelial cell adhesion molecule) we found significantly enhanced angiogenesis in the 






Fig. 27. Reactive gliosis and angiogenesis in Pten mutant mice. (a) Transcriptome analysis of 
Pten cKO and controls revealed no general upregulation of microglia and macrophage antigens, 
such Aif1 (Iba1, p=0.1083), Cd68 (p=0.9555), Itgam (CD11B, p=0.4901). Cd163 a marker of anti-
inflammatory or immunoregulatory M2 microglia/macrophages demonstrated a 7-fold upregulated at 
the RNA level in the mutant GL (p=0.0004) (b) Immunohistochemistry and quantification of Iba1 
revealed a significant difference in the ML of Pten cKO mutants, compared to controls (p=0.0413), 
whereas the numbers in the GL are unchanged (p=0.5484). (c,d) Likewise, the number of Mac-3 
positive microglia cells and the GFAP+ positive are is increased in the mutant ML (Mac-3: p=0.0295; 
GFAP+ area: p=0.0406) but not in the GL (Mac-3: p=0.9888; GFAP+ area: p=0.141). (e) Percentual 
area covered by microvessels is increased in the Pten mutant GL when compared to controls 
(quantitated on lobe 5 of cerebellar parasagittal paraffin sections immunostained for the endothel cell 
marker CD31). N=3 per genotype; age: 2.5 months. Data are means ± s.e.m. *p<0.05; ***P < 0.001, 





3.5.5.1 No signs of gliosis in NEX-CreERT2*PtenloxP/loxP mice 
Since we found minor changes of Iba1, Mac-3 and GFAP in the Pten cKO ML (Fig. 27b,c,d) 
we analyzed Nex-CreERT2*PtenloxP/loxP mutants with only 4% GC recombination (Fig. 17a), 
but significant myelination (Fig. 17c-f). Quantification for “gliosis” markers revealed no 
detectable differences in the ML and GL of Nex-CreERT2*PtenloxP/loxP mutants compared to 
controls (Fig. 28a-c), even 28 weeks after recombination (Fig. 17b). This suggests, that the 
upregulation of Iba1+, Mac-3+ and GFAP+ cell numbers in the ML of Pten cKO are not a 
necessary primary trigger for de novo myelination. 
 
 
Fig. 28. No activation of microglia and astrocytes in the NEX-CreERT2*PtenloxP/loxP cerebellum. 
(a) Nex-CreERT2*PtenloxP/loxP mutants do not exhibit more Iba1+ microglia in the ML (p=0.8886) nor 
in the GL (p=0.516). (b) Quantification of Mac-3+ cell revealed no significant difference (ML: 
p=0,1494; GL: p=0,7067). (c) Similarly, GFAP+ area is similar in Nex-CreERT2*PtenloxP/loxP mutant 
and control GL (p=0.9487) and ML (p=0.4998). Quantifications were performed on parasagittal 
sections of the cerebellar vermis; n=3 per genotype; age, 30 weeks. Data are means ± s.e.m.; 







3.5 Inactivation of Pten in CA3 neurons 
Are all CNS axons subject to de novo myelination when the Akt/mTOR pathway is artificially 
hyperactivated in the corresponding neuron? To target this question, we inactivated Pten in 
the forebrain, using the Nex-CreERT2 driver line intercrossed with floxed Pten mutants 
(Lesche et al., 2002). In contrast to the sparse recombination of cerebellar granule cells 
(see Fig. 17a) almost all hippocampal pyramidal neurons recombine after 5 consecutive 
days of tamoxifen treatment (P10-P15) (Agarwal et al., 2012) (Fig. 29a,b). However, when 
analyzed 28 weeks after tamoxifen induced inactivation of Pten, no ectopic OPC 
proliferation and no de novo myelination of CA3 Schaffer collaterals (Fig. 29c) could be 
observed. Furthermore, quantification of the total number of CNP positive cells and MBP+ 
area in the hippocampus of controls and Nex-CreERT2*PtenloxP/loxP mutants revealed no 
significant difference (Fig. 29d,e).  
 
 
Fig. 29. Pten inactivation in principal neurons of the hippocampus. (a) Tamoxifen treatment 
schemes of Nex-CreERT2*PtenloxP/loxP mutant mice. Cre-mediated activation of a lacZ reporter gene 
in CA3 neurons (CA3) revealed almost a 100% recombination efficiency upon tamoxifen treatment 
from P10-P15 (b). For further analysis, Nex-CreERT2*PtenloxP/loxP mutant mice and controls were 
injected with tamoxifen from P10-P15 and analysed 28 weeks later. (c) Nex-CreERT2*PtenloxP/loxP 
mutant mice exhibited the identical distribution of CNP+ oligodendrocytes in the hippocampus. (d) 
Quantification of CNP+ oligodendrocytes revealed no significant difference (p=0.8451). (e) Similar, 
the MBP+ area is unchanged in Nex-CreERT2*PtenloxP/loxP mutant mice compared to controls 
(p=0.7849). Quantified on coronal sections of the forebrain; n=3 mice each genotype and age. Data 





Since somata of Nex-CreERT2*PtenloxP/loxP mutant CA3 neurons were enlarged when 
quantified on H&E stained paraffin sections and on electron micrographs (Fig. 30a,b) we 
argue that hyperactivation of PI3K/Akt/mTOR pathway is not always sufficient to trigger 
CNS myelination. Inhibitory signals may “protect” forebrain neurons, as myelination can 
interfere with axonal sprouting and neuronal plasticity in the adult brain (Schwab and 
Strittmatter, 2014). However, we have no formal proof that the Schaffer collaterals were 
sufficiently enlarged. Electron micrographs and serial block-face scanning electron 
microscopy did not allow us to unequivocally identify Schaffer collaterals. 
 
 
Fig. 30. Enlargement of CA3 neurons upon Pten inactivation. (a) Nex-CreERT2*PtenloxP/loxP 
mutant mice exhibited significantly enlarged hippocampal CA3 neurons, when quantified in H&E 
stained paraffin sections. Pten was inactivated by injecting tamoxifen from P10-P15. Quantification 
was done 28 weeks later (n=3 per genotype; 40 cells per animal, p=0.0005). (b) Similar enlarged cell 










3.6 Hamartoma formation in aged Pten mutants 
We note that later in life, many mice older than 11 months developed ataxia and hindlimb 
paralysis (Video 2, can be found on the included CD-ROM or on Nature Neuroscience 
webpage http://www.nature.com/neuro/journal/vaop/ncurrent/fig_tab/nn.4425_SV2.html), 
possibly due to cerebellar hamartomas at that older age, which preferentially affected the 
inferior and posterior lobes (Fig. 31a). Granular cells, preferentially located in the inferior 
and posterior lobes of the cerebellum, developed a secondary and focal hyperplasia that 
was clearly more pronounced than the hypertrophy underlying the myelination phenotype 
(Fig. 31b). Calbindin immunohistochemistry revealed a Purkinje cell loss (Fig. 31c), next to 
reduced central white matter (immunostained for CNP, oligodendrocyte and myelin specific 
marker) (Fig. 31d) and signs of inflammation (activated microglia cells, immunostained for 
Mac-3). Furthermore, vascularization was enhanced (Fig. 31e). These features collectively 
model features of human Lhermitte Duclos disease (LDD), a dysplastic gangliocytoma of 







Fig. 31. Pten mutant mice as a model of Lhermitte-Duclos disease. (a) Gallyas silver impregnation 
of cerebellar parasagittal sections reveals a focal pathology (asterisks) in aged Pten mutants that is 
preferentially localized to the inferior lobe (IL) and the posterior lobe (PL). Pathology is characterized 
by secondary focal hypergrowth of GC immunostained for NeuN (arrowheads in b; age 1 year; boxed 
area magnified on the right), loss of Purkinje cells immunostained for Calbindin (arrowheads in c; 
age, 1 year; boxed area magnified on the right), loss of central white matter immunostained for CNP 
(arrowheads in d; age, 1 year; boxed area magnified on the right), and presence of activated 
microglia cells immunostained for Mac-3 (in e; age, 1.5 years; boxed area magnified on the right) 
and enhanced vascularization (boxed area in e magnified on the right and further magnified in inset). 






4.1 Axon caliber and PI3K dependent induction of myelination 
During myelination but also in remyelination, a plethora of cell intrinsic and extrinsic 
signaling molecules have been suggested as modulators and coordinators of the complex 
process of axonal ensheathment by oligodendrocytes (Hsieh et al., 2004; Mcmorris et al., 
1986; Miron et al., 2013; Van't Veer et al., 2009; Vanderpal et al., 1988; Xiao et al., 2010; 
Xiao et al., 2012). However, recent data challenged the idea that axonal signals are at all 
required to initiate and coordinate this process. Here, in experiments by Lee, 2012, even 
artificial nanofibers with threshold caliber diameters above 0.4 µm became myelinated by 
oligodendrocytes in the absence of any axonally derived guidance signals in vitro. This 
study effectively uncoupled the role of molecular cues from biophysical properties of the 
axon and demonstrated a dependency of myelination on axon caliber in the CNS (Lee et 
al., 2013; Lee et al., 2012). Thus, one obvious possibility would be that an axonal caliber 
above a certain key-threshold, is sufficient to instruct myelination in vivo.  
Several approaches in PNS analyses have addressed the correlation between myelination 
and axon caliber (Duncan and Hoffman, 1997; Matthews, 1968). Indeed, axons larger than 
1 μm are preferentially myelinated (Duncan and Hoffman, 1997; Matthews, 1968; Salzer, 
2003). Back in 1989, Voyvodic increased the caliber of normally unmyelinated sympathetic 
postganglionic axons in the PNS, by increasing the size of the peripheral target tissue they 
innervate (Voyvodic, 1989). Subsequently, this axonal caliber increase induced de novo 
myelination by Schwann cells. Based on this observation, it was concluded, that i) axon 
caliber in the PNS is in fact the crucial determinant of whether or not an axon becomes 
myelinated and that ii) the production of myelin is likely determined by a signal from the 
axon that increases along with axon caliber (Aguayo et al., 1976; Voyvodic, 1989; Weinberg 
and Spencer, 1976). Meanwhile, the instructive signal on the axon has been identified as 
Neuregulin 1 that activates ErbB downstream signaling in Schwann cells and is the key 
trigger for myelination in the PNS (Michailov et al., 2004; Taveggia et al., 2010). Neuronal 
overexpression of Nrg1 induces hypermyelination and the reduction of Nrg1 expression 
causes a hypomyelination (Michailov et al., 2004). However, this axonal growth factor is 
dispensable for CNS myelination (Brinkmann et al., 2008), which leaves the neuronal 
factors that control OPC development and myelination in vivo poorly understood. 
Nevertheless, and in contrast to Schwann cells, oligodendrocytes are able to follow a more 
“default” pathway and even myelinate artificial carbon nanofibers (Lee et al., 2013; Lee et 
al., 2012). However, in this artificial model, oligodendrocytes engage with the nanofibers, 
start membrane ensheatment, but they fail to generate multiple wraps and compact myelin 





factors and cytokines, including Pdgf, Fgf2, Igf1, Bdnf, Nt3, Cntf and Lif, have been identified 
as regulators of the proliferation and differentiation of oligodendrocyte lineage cells. A role 
for IGF1 (insulin-like growth factor 1) was for example demonstrated by the analysis of 
mouse mutants. Homozygous Igf1-/- mice, exhibited decreased numbers of 
oligodendrocytes and a reduction of white matter structures (Beck et al., 1995), while 
transgenic mice overexpressing Igf1 developed an upregulation of oligodendroglial myelin 
synthesis (Carson et al., 1993). This strengthens the hypothesis, that beside the axon 
caliber an big orchestra of many different positive and negative signals from various cells 
and the extracellular environment is needed to modulate and control for proper and timely 
myelination. As mentioned in the introduction, most of the already known signals and growth 
factors, with putative effects on oligodendrocyte lineage cells, are produced and secreted 
by astrocytes and endothelia cells or are of unknown origin. Signal cues directly from axons 
are largely unknown and need to be discovered. To resolve this lack of knowledge, we 
genetically induced, in analogy to the classical work from Voyvodic (1989), an axonal caliber 
increase (by hyperactivating Akt/mTOR-dependent downstream signaling in normally 
unmyelinated neurons), which was followed by the proliferation of wt OPCs in the molecular 
layer, their maturation to oligodendrocytes, and the de novo myelination of parallel fibers 
starting at around postnatal day 40 (P40) and progressing with age. Interestingly, once the 
caliber threshold (0.25 μm) for being myelinated was achieved, oligodendrocytes showed 
no general preference for especially larger caliber axons. This is consistent with previous 
electron microscopy findings in spinal cords from rats, where single oligodendrocytes 
myelinated axons with different calibers (Waxman and Sims, 1984). The average diameter 
of a wildtype parallel fiber is around 0.2 μm and it is normally unmyelinated. Nevertheless, 
some parallel fibers in larger mammals, such as cats and macaques surpass the critical 
size limit and become myelinated (Lange, 1976). This may suggest that parallel fibers are 
in principle quite susceptible to myelination but they are simply not preferentially because 
of their small caliber. Furthermore, since the ML is anyway not populated by 
oligodendrocytes there may also be no need for the Pf to express an additional battery of 
molecules that would actively hinder myelination. This uniqueness of Pf might explain, why 
we were not able to induce de novo myelination of other normally unmyelinated CNS axons, 
the Schaffer collaterals of the hippocampus, with the very same genetic mutation of the 
Pten gene. We hypothesize that Schaffer collaterals likely have a higher need to express 
more inhibitory signals than Pf, in order to exclude their axons from myelination, since their 







4.2 Regulation of OPC proliferation, differentiation and CNS myelination 
Understanding the signaling mechanisms that trigger oligodendrocyte precursor cell (OPC) 
proliferation and myelination in the central nervous system (CNS) in vivo is of key 
importance for the therapy of diseases, such as multiple sclerosis, in which endogenous 
repair mechanisms fail. Numerous signaling cues must be considered, including 
myelination-promoting and inhibiting factors that could act on OPCs and oligodendrocytes, 
as well the size and electrical activity of putative target axons (Piaton et al., 2010; Taveggia 
et al., 2010).  
Neurons release growth factors in an activity dependent manner and neuronal activity is 
known to promote myelination and proliferation of OPCs (Karadottir and Attwell, 2007). 
Moreover, OPCs receive synaptic input from Pf in the cerebellar ML (Lin and Bergles, 2004) 
and synaptic input from unmyelinated axons to OPCs modulates their proliferation (Mangin 
et al., 2012) and myelination (Wake et al., 2011). Thus we asked in our mutant mouse 
model, if increased OPC proliferation and myelination was induced by changes resulting 
from alterations in granular cell activity. However, we found no differences between mutants 
and controls in the frequency of the spontaneous synaptic input that OPCs receive from 
parallel fibers or in the frequency of spontaneous inputs in Purkinje cells at the age of P7-
P100, i.e. at times of ongoing OPC proliferation and myelination in the Pten mutant ML. 
These results suggest, that none of the observed oligodendroglial phenotypes was induced 
by changes in granular cell electric activity. 
Hypothetically, de novo parallel fiber myelination in the mutants could have been caused by 
down-regulating axon-bound inhibitory neuronal ligands that bind to known inhibitory 
pathways of oligodendrocyte development, such as the Notch1 pathway (Taveggia et al., 
2010). It is well established, that at early developmental stages, OPC differentiation and 
myelination can be inhibited by the interaction of axonally expressed Jagged to 
oligodendroglially expressed Notch (Genoud et al., 2002; Givogri et al., 2002; Wang et al., 
1998; Zhang et al., 2007). One specific Notch1 ligand that appeared 2.5 fold downregulated 
in our transcriptome analysis of laser captured GC layer of Pten mutants was Dner, a protein 
strongly expressed in several types of post-mitotic neurons (Eiraku et al., 2002). Whether 
this down regulation of the neuronal transmembrane protein Dner plays a role in the process 
of ectopic myelination of Pf has to be addressed in more detail in the future. 
We concentrated instead more on the idea that also the down regulation of soluble/released 
inhibitory signals might have been instructive for de novo myelination of Pf. To test for this 
possibility, we intercrossed flox Pten mutants to a Nex-CreERT2 driver line (Agarwal et al., 





(Agarwal et al., 2012). However, when analyzed 28 weeks after tamoxifen injections, loss 
of Pten in this small fraction of granule cells was still sufficient to significantly increase the 
numbers of mature oligodendrocytes and the MBP positive area in the cerebellar molecular 
layer. This makes it unlikely that soluble inhibitory factors (still expressed by the vast 
majority of non-recombined granule cells) regulate Pf myelination. Hence, we focused next 
on genes for soluble growth factors and signaling molecules, for which the corresponding 
mRNAs were upregulated in the hypertrophic GL and which are ligands of established 
pathways in oligodendrocytes that instruct myelination (Goebbels et al., 2010; Ishii et al., 
2013; Santra et al., 2012). 
Transcriptome analysis resulted in a first list of candidate factors upregulated in Pten cKO 
and selected by annotation. mRNAs with higher expression in the mutants included for 
example Bdnf, which we selected for a proof-of-principle in vivo analysis, to address the 
significance of this list of candidates. Bdnf is already believed to be involved in 
oligodendroglia lineage cell development and myelination, although no clear picture has 
emerged yet. On the one hand, conditional inactivation of Bdnf in neurons did not induce a 
difference in the density of Olig2+ cells in the striatum and no effect on myelination in the 
optic nerve (Rauskolb et al., 2010). On the other hand it has been shown in Bdnf 
heterozygous mice that NG2+ cells as well as the protein amount of MBP, MAG and PLP 
were reduced in the basal forebrain (Vondran et al., 2010). When we analyzed double 
mutant mice, which lacked both Pten and Bdnf in cerebellar granule cells we obtained the 
unexpected result, that the mutants had more (not less) proliferating OPCs, 
oligodendrocytes and myelin sheaths in the ML, however the myelin sheath thickness of 
single sheaths was reduced. 
We reasoned that Bdnf is a "pro-differentiation" signal with limited efficacy for OPCs in our 
mutants. Accordingly, it's loss in double mutants initially increased the weight of the "pro-
proliferative" signals and thereby also the number of OPCs generated in the mutant ML. 
However, at a later stage the remaining "pro-differentiation" factors were still sufficient to 
trigger OPC differentiation and myelination, possibly with some temporal delay. This finding 
suggested that not one key factor but many factors (each with a measurable but limited 
range of efficacy) play a role in orchestrating oligodendrocyte lineage cell progression in 
our mutants. Inactivating one player, such as Bdnf has a moderate effect on imbalancing 
the whole system. In line with this finding, until now, not a single neuronal mutation has 
been reported in the literature that completely prevents CNS myelination, even in large 





Because of the suggested complexity of the cocktail of orchestrating factors, we turned to 
in vitro assays to further validate some of our candidate factors. In these experiments 
recombinant forms of our upregulated candidate genes triggered different responses in 
oligodendrocyte lineage cells. Pleiotrophin is a member of the neurite growth-promoting 
factor family (Kretschmer et al., 1991). Adding the recombinant form of Pleiotrophin to our 
cocultures revealed an induction of myelination. This is in line with the recent finding that 
Pleiotrophin is expressed and released from demyelinated neurons and binds as an 
inhibitory ligand to PTPRZ (Protein tyrosine phosphatase receptor type z) in OPCs, which 
results in induced OPC differentiation for remyelination (Kuboyama et al., 2015). In our 
experiments, Fgf1, a member of the heparin growth factor family demonstrated a pro-
proliferative role for OPCs, when tested in cocultures. It was the only factor, next to our 
positive control Pdgf that resulted in significantly more OPC proliferation in culture. This is 
in line with several in vitro studies, that showed similar findings for Fgf1 and Fgf2 (Engele 
and Bohn, 1992). Neurons and astrocytes are able to produce and secrete different Fgfs 
(Becker-Catania et al., 2011; Elde et al., 1991; Gomezpinilla et al., 1992; Matsuyama et al., 
1992; Nakamua et al., 1999; Riva and Mocchetti, 1991), whereas oligodendrocyte lineage 
cells express the corresponding Fgf receptors in a developmentally regulated manner 
(Bansal et al., 1996; Fortin et al., 2005). Fgfr1 and Fgfr3 are expressed by OPCs, whereas 
Fgfr2 and additionally Fgfr1 are expressed by differentiated oligodendrocytes (Bansal, 
2002). Mice lacking both Fgfr1 and Fgfr2 in oligodendrocyte lineage cells, revealed 
surprisingly no phenotype in OPC proliferation and differentiation. Although, the growth of 
CNS myelin was strongly inhibited (Furusho et al., 2012). This suggest, that the in vivo 
function of Fgf signaling is more complex and probably not limited on proliferation (Furusho 
et al., 2012). Timp3, one out of four members of the tissue inhibitor metalloproteinases 
family, induced myelination in our cocultures. This function of Timp3 on promoting 
myelination is novel. However it has been shown before that inactivation of Timp1, a 
member of the same family, induced a reduced myelin repair following a demyelinating 
injury in mice (Crocker et al., 2006). Additionally, the formation of compact myelin was 
delayed accompanied by a reduction of NG2+ OPCs (Moore et al., 2011). Tmsb4x is a G-
actin sequestering peptide (Moon et al., 2010) and is known to increase 
oligodendrogenesis, although the molecular mechanisms are unclear (Santra et al., 2012). 
Threating cocultures with the recombinant form of Tmsb4x increased the myelination index 
in our experiments, suggesting (in line with the literature) a positive effect on myelination. 
Activin A (Inhba, forming the biologically active dimer Activin A) belongs to the TGF-β 
protein superfamily (Kingsley, 1994). Myelination in vitro was induced in our cocultures by 
adding recombinant Activin A. More importantly Activin A also emerged as a differentiation 





report, in which Activin A was identified as a microglia (M2) cell-derived oligodendrocyte 
differentiation factor. Blocking Activin A resulted in the inhibition of remyelination in 
cerebellar slice cultures (Miron et al., 2013). Activin A is in principle able to signal through 
a combination of type I and II transmembrane serine/threonine kinase receptors (Harrison 
et al., 2005; Tsuchida et al., 2008), via Smad2/3/4 dependent complexes or Smad-
independent pathways such as MAPK (ERK1 and ERK2), or PI3K pathway (Tsuchida et 
al., 2009). By blocking the specific signaling pathways one by one, we could demonstrate 
that the pro-differentiation activity of Activin A on oligodendrocyte lineage cells required the 
activation of MAPK, but not PI3K or SMAD3, to be effective. 
Our experimental setup and the emerged de novo myelination of the cerebellar molecular 
layer in Pten mutant mice, suggested the instructive role of a primarily neuronal 
(PI3K/Akt/mTOR-dependent) developmental program for myelination. Although, down-
stream of this switch, as noted in the results part and annotated by the database from 
http://web.stanford.edu/group/barres_lab/brain_rnaseq.html (Zhang et al., 2014) not all 
newly identified differentiation/myelination factors are necessarily of neuronal origin. 
Several upregulated immune modulatory factors were revealed by our transcriptome 
analysis (like. Nts and Ninj1) with a role in immune cell migration (Ifergan et al., 2011; 
Katsanos et al., 2008). However, as shown in the results part, general microglia and 
macrophage marker antigens, including Aif1/Iba1, Cd68 and Itgam/CD11B were not 
differentially regulated. This is in line with immunohistochemical analysis of microglial 
marker antigens and respective quantifications, which revealed no difference in cell 
numbers of Iba1+, Mac-3+ and GFAP+ cells in the GL between mutants and controls at the 
age of 2.5 months. However, Cd163 a marker of anti-inflammatory (M2 type) 
microglia/macrophages was 7-fold upregulated at the mRNA level in the mutant GL and the 
ML contained significantly more microglial cells and astrocytes, when quantified by 
immunohistochemistry. This prompted the idea to analyze the potential impact of microglial 
cells more in detail in Nex-CreERT2*PtenloxP/loxP mutants in which less cells were 
recombined (only 4% of GC recombination, but significant de novo myelination). No 
elevation of gliosis markers were visible in the ML nor in the GL in Nex-CreERT2*PtenloxP/loxP 
mutants. Thus, we conclude that the de novo myelination of the ML in Pten cKO is not 
initiated by microgliosis. However, subtle gene regulation changes in existing microglia or 
astrocytes may have had secondary impact but were for sure downstream of the primary 
instructive signal, which is for sure neuronal as defined by the specific genetic intervention 
in GC. Interestingly we also identified several factors (Vegfc, Apcdd1, Igfbp7) in our genetic 
screen that are exclusively expressed in endothelial cells. Accordingly, 
immunohistochemistry for CD31 (cluster of differentiation 31/ PECAM-1, platelet endothelial 





2009) demonstrated a significantly higher angiogenesis in the mutant GL at the age of 2.5 
months. This finding seems interesting, since recent studies suggested an instructive role 
of endothelia cells in the regulation of oligodendrocyte lineage cells. For example, the 
proliferation of OPCs was induced by the presence of endothelia cells in a trans-well culture 
system. Since the different cell types were cultured with no direct cell-cell contact, the 
finding indicated a secretion of putative oligo-supportive factors by endothelia cells (Arai 
and Lo, 2009). In summary the role specifically of microglial cells and vasculature as 
bystanders of myelination awaits to be further explored. 
 
4.3 Utilization of acquired knowledge from PI3K dependent de novo 
myelination 
We identified a neuronal, PIP3-dependent switch, that instructed the entire cascade of 
oligodendrocyte lineage cell development and de novo myelination, at least in part by direct 
or indirect upregulation of newly identified factors, such as Fgf1, Pleiotrophin, Timp3, 
Thymosin beta 4, and Activin A. One major dispute in demyelinating diseases like multiple 
sclerosis is about the failure to repair lesioned areas. Although OPCs are present, they often 
fail to differentiate into mature oligodendrocytes and to remyelinate axons that lost their 
myelin sheaths. Remyelination is a regenerative mechanism, protecting demyelinated 
axons by restoring myelin sheaths (Irvine and Blakemore, 2008). Genetic lineage tracing in 
transgenic mice identified oligodendrocyte lineage cells as an endogenous source of mature 
and myelinating oligodendrocytes in the healthy adult CNS (Rivers et al., 2008). It would be 
important to unveil the signals that promote oligodendrocyte differentiation during 
development and to use this knowledge to promote remyelination. With the help of our 
transcriptomic approach, we identified several known and also novel signaling cues with a 
putative effect on the oligodendrocyte lineage cell development. The application of these 
factors in demyelinating disorders, such as mouse models of multiple sclerosis would be a 
promising strategy in preclinical studies to protect degenerating axons by promoting 
remyelination. Nevertheless, a major problem is to administer factors like Bdnf, Fgf1, Timp3, 
Pleiotrophin, Tmsb4x or Activin A. Bdnf, for example cannot be transcytosed through the 
blood-brain barrier (BBB) in vivo (Pardridge et al., 1994). For the other identified factors, not 
much is known about their ability to pass the blood brain barrier. Some studies in rats/mice 
implanted miniosmotic pumps or used intraventricular infusion of growth factors like VEGF 
(Proescholdt et al., 1999) or BMP4 (bone morphogenic protein) (Sabo et al., 2011). 
Intraventricular infusion of BMP4 during demyelination increased the proliferation of OPCs 
(Sabo et al., 2011). In a very recent study, Bdnf was injected intravenously in rats after white 





brain barrier (Schabitz et al., 2007). Bdnf treated animals showed less functional deficits 
and depicted an increased proliferation of OPCs (Ramos-Cejudo et al., 2015). These data 
support the concept of growth factor mediated oligodendrogenesis and treatment of 
demyelination in mouse models and patients.  
 
4.4 Pten deficiency in granular cells: A new mouse model for Lhermitte-Duclos 
disease 
Especially upon aging, our conditional Pten mutant mice are a novel and suitable model for 
Lhermitte Duclos disease (LDD), which is superior to the existing ones (Backman et al., 
2001; Kwon et al., 2001). LDD is characterized by diffuse hypertrophy of the granular layer, 
loss of white matter and slowly growing tumors (hamartoma) of the cerebellum (Eng, 2000). 
Patients develop a macrocephaly accompanied by ataxia and seizures, usually affecting 
patients aged 30-50 years (Giorgianni et al., 2013). The normal architecture of the 
cerebellar cortex is abrogated and a secondary Purkinje cell loss can be observed 
(Backman et al., 2001). Although the exact cause in patients is unknown, mutations in the 
PTEN gene have been identified (Blumenthal and Dennis, 2008). By inactivating a loxP 
flanked Pten gene by using a GFAP-Cre driver line, two mouse models were created that 
mimic some of the characteristic symptoms of the disease, such as ataxia, seizures, 
Purkinje cell loss and hypertrophy of granule cells (Backman et al., 2001; Kwon et al., 2006). 
However, none of the animals developed hamartomas, possibly due to the short life span 
of this mutants, that was owed to the fact that rather general Cre driver lines targeting 
primarily astroglial cells were used. Most of the mutants died around 29 weeks (Backman 
et al., 2001) or between 9 and 48 weeks (Kwon et al., 2001) in consequence of seizures 
and ataxia. In contrast, our model closely resembles the pathology of human patients, 
including hamartoma formation, white matter reduction and massive Purkinje cell loss and 
may contribute in further experiments to a better understanding of this disease. Also a 
further assessment of the transcriptomic profiles of the mutants including the upregulated 
soluble factors might be interesting, since they may qualify as specific tumor markers with 
diagnostic value for LDD. 




5. Material and Methods 
5.1 Mouse mutants 
All experiments were conducted according to the Lower Saxony State regulations for the 
use of experimental animals in Germany as approved by the Niedersächsisches Landesamt 
für Verbraucherschutz und Lebensmittelsicherheit (LAVES) and according to UK 
government animal use regulations. Mice were housed in groups in individually ventilated 
cages under a 12:12h light/dark cycle with access to food and water ad libitum. If not stated 
otherwise, for molecular, histological, electrophysiological, electron microscopical and 
biochemical experiments, female and male mice were included in the experiments and were 
randomly allocated to experimental groups according to age and genotype. All animal 
experiments were conducted in a single blinded fashion towards the investigator. 
Inclusion/exclusion criteria were pre-established. Animals were excluded from the 
experiment when showing impaired health conditions not attributable to genotype or 
experiment or when the weight difference to the average group weight was larger than 10%. 
With respect to the outcome assessment, exclusion criteria were determined with Grubbs' 
test (ESD method), using the statistical software GraphPad (Prism). No animals or samples 
had to be excluded with these criteria in any of the experiments. 
 
Mice mutant for PtenloxP/loxP, Tg(m6-Cre)B1LFR, Nex-CreERT2, Nrg1loxP/loxP, BdnfloxP/loxP, 
Plp1-DsRed, Rosa26-lacZ and Ng2-EYFP were genotyped as described (Agarwal et al., 
2012; Funfschilling and Reichardt, 2002; Hirrlinger et al., 2005; Karram et al., 2008; Lesche 
et al., 2002; Li et al., 2002; Rauskolb et al., 2010; Soriano, 1999). Tg(m6-Cre)B1LFR, Nex-
CreERT2, Nrg1loxP/loxP, BdnfloxP/loxP, Plp1-DsRed, Rosa26-lacZ and Ng2-EYFP mutants were 
on C57BL/6N background, whereas PtenloxP/loxP mutants and thus all compound mutants 
harboring PtenloxP alleles were on mixed C57BL/6N-SV129 background. For genotyping, 
genomic DNA was isolated from tail biopsies (InvisorbSpin Tissue Mini kit, Invitek) 
according to the manufacturer’s directions and subjected to routine PCR methods. 
 
































5.2 BrdU labeling 
Mice received 5’-bromo-deoxyuridine (BrdU, Sigma Aldrich) by daily intraperitoneal 
injections (50 µg/g of body weight) for 20 consecutive days. Mice were sacrificed 4 hours 








5.3 Histology and immunohistochemistry 
Mice were anaesthetized with avertin (Sigma–Aldrich) and perfused with 15 ml of Hanks 
balanced salt solution (HBSS, PAA laboratories, Pasching, Austria) followed by fixative (4% 
PFA, 0.1M Phosphate buffer, 0.5% NaCl). Paraffin sections of the brain (5 µm) were 
deparaffinized using xylene and isopropanol and rehydrated in a descending ethanol series. 
Antigen unmasking was performed by boiling for 10–40 min in citric buffer, pH 6, or Tris 
EDTA, pH 9. Sections were blocked in 20% goat serum in PBS/BSA for 1 h and incubated 
with primary antibodies in 5% goat serum in PBS/BSA for 2 h at 37°C or overnight at 4°C. 
Detection was performed by using Alexa Fluor 488-, 555- and 633-conjugated secondary 
antibodies (1:1000, Thermo Fisher Scientific, #A-28175, #A-11034, #A-21212, #A-21422, 
#A-27039 and #A-21094) and by using biotinylated secondary antibodies, followed by 
diaminobenzidine (DAB) (LSAB2 Kit, Dako, #K0675; Vectastain Kit, Vector Laboratories, 
#BA-9400, #PK-6100). Primary antibodies were directed against BrdU (1:200, Chemicon, 
#MAB3424), CAII (1:200, kindly provided by S. Ghandour, Strasbourg, PMID: 118210), 
Calbindin (1:600, Sigma, #C9848), Caspr (1:100, NeuroMab, #75-001), CD31 (1:100, 
Dianova, #DIA-310), CNPase (1:150, Sigma, #C5922), GABAA receptor 6 subunit (1:500, 
Chemicon, #AB5610), GFAP (1:200, Novocastra, #NCL-GFAP-GA5), Iba1 (1:1000, Wako, 
#019-19741), MBP (1:200, Covance, #SMI-94R); NaV1.6 (1:500, Alomone Labs, #ASC-
009); NeuN (1:200, Chemicon, #MAB377); Olig2 (1:200, kindly provided by J. Alberta, 
PMID: 15198128), and Mac-3 (1:500, BD Pharmingen, #553322). 5 µm microtome sections 
(Microm HM400) were also stained by hematoxylin–eosin (HE) to study cytoarchitecture. 
Myelinated fibers were visualized by Gallyas silver impregnation as described (Lappe-
Siefke et al., 2003). All images showing immunohistochemical analyses and stainings were 
successfully repeated at least three times.  
 
5.4 In situ hybridization  
In situ hybridization was performed as described (Bormuth et al., 2013), by our collaborators 
Kuo Yan and Dr. Ingo Bormuth. A Myrf probe corresponding to 941bp from Myrf 3’ UTR was 
kindly provided by B. Emery (Jungers Center for Neurosciences Research, Department of 








5.5 Electron microscopy 
Mice were anaesthetized with avertin (Sigma–Aldrich) and perfused with 15 ml of Hanks 
balanced salt solution (HBSS, PAA laboratories, Pasching, Austria) followed by fixative (4% 
PFA, 0.1M Phosphate buffer, 0.5% NaCl, 2.5% glutaraldehyde). At parasagittal plane, 
cerebellar lobulus 5 was dissected, contrasted with 1% osmium tetraoxide and embedded 
in epoxy resin. Semi-thin (0.5mm) and ultra-thin (50–60 nm) sections were cut, using a 
microtome (RM 2155, Leica Microsystems, Wetzlar, Germany) with a diamond knife (Histo 
HI 4317, Diatome, Biel, Switzerland). Semi-thin sections were stained with azur-II-
methylenblue for 1 min at 60°C. Ultra-thin sections were stained with 2% uranylacetate (30 
min) and 1% lead citrate solution (12 min) and analysed using a LEO EM912AB electron 
microscope (Carl Zeiss NTS, Oberkochen, Germany). Images were taken with an on-axis 
2048x2048 CCD camera (Proscan, Scheuring, Germany). 
 
5.6 Electrophysiology  
Electrophysiology was performed by our collaborators Sonia Spitzer and Ragnhildur Thóra 
Káradóttir by cuting parasagittal cerebellar slices (225 μm) using a vibrating blade 
microtome (Leica VT1200S) from P7-P100 Ng2-EYFP+/-*Tg(mα6)-Cre*PtenloxP/loxP mice 
(mutants) and Ng2-EYFP+/-*Pten loxP/loxP mice (controls), culled by cervical dislocation in 
accordance with UK government animal use regulations. After dissection, the brain was 
placed in a cooled (∼1ºC) oxygenated (95% O2–5% CO2) Krebs solution containing (mM): 
126 NaCl, 24 NaHCO3, 1 NaH2PO4, 2.5 KCl, 2.5 CaCl2, 2 MgCl2, 10 D-glucose (pH 7.4). 
In addition, kynurenic acid was included in order to block glutamate receptors, which might 
be activated during the dissection procedure and cause cell damage. During experiments 
slices were superfused at 22±1ºC with HEPES- buffered external solution containing (mM): 
144 NaCl, 2.5 KCl, 10 HEPES, 1 NaH2PO4, 2.5 CaCl2, 10 glucose, 0.1 glycine (to co-
activate NMDA receptors), 0.005 strychnine (to block glycine receptors), pH set to 7.4 with 
NaOH, bubbled with 100% O2. OPCs were identified by EYFP expression and whole-cell 
voltage clamped. Recording electrodes had a resistance between 5-9MΩ when filled with 
an internal solution comprising (mM): 130 K-gluconate, 4 NaCl, 0.5 CaCl2, 10 HEPES, 10 
BAPTA, 4 MgATP, 0.5 Na2GTP, 2 K-Lucifer yellow, pH set to 7.3 with KOH and the 
uncompensated series resistance was 40±1MΩ and electrode junction potentials (- 14mV) 
were compensated for. A Multiclamp 700B (Molecular Devices) was used for voltage clamp 
data acquisition. Data were sampled at 50kHz and filtered at 10kHz using pClamp10.3 
(Molecular Devices). 
 




5.7 Synaptic current analysis 
A synaptic current was defined to occur if its amplitude was bigger than twice the standard 
deviation of the baseline current noise and its 10-90% decay time was longer than its rise 
time. Events were detected and analysed with pClamp 10.3 (Molecular Devices) and the 
Strathclyde Electrophysiology Software package WinEDR V3.3.7 WinWCP V4.6.2. 
 
5.8 Laser-capture microdissection, RNA isolation and linear amplification, 
and microarray hybridization 
Mice were killed at 3 months of age by cervical dislocation, total brains were dissected and 
frozen on dry ice, protected with parafilm and stored at -80°C. Serial coronal cryosections 
(20 µm) were prepared using a Leica CM3000 Cryostat, mounted on polyethylene 
naphthalate membrane frame slides (Arcturus), stained with thionin, and dried in an 
ascending ethanol/xylene series. For laser-capture microdissection (LCM), a Veritas 
Microdissection System (Arcturus) was used with slides mounted and stained the same 
day. Cerebellar GL were dissected by ultraviolet laser (laser power set to 3.2–4.2) and 
attached to CapSure LCM caps using an infrared laser (power set to 80%). Caps were 
collected in 0.5 ml Eppendorf tubes containing 100 µl of RNeasy Lysis Buffer (Qiagen) and 
stored at -80°C. Total RNA was isolated from LCM tissue using the Micro RNeasy Kit 
(Qiagen) according to the instructions of the manufacturer except that RNA was eluted from 
the column with 10µl of water followed by precipitation with NaAcetate (pH 5.2, f.c. 0.3M) 
and PelletPaint (Novagen) as carrier. Two-round amplification and biotin-labeling, 
hybridization to mouse MOE230A 2.0 genechips (Affymetrix), washing and scanning was 
essentially as described (Rossner et al., 2006) with 3 biological replicates for each 
genotype. Data analysis was performed using Genomics Suite (Partek Inc.). Raw data were 
normalized using the RMA algorithm and differentially expressed genes were identified with 
ANOVA according to the workflow suggested by the manufacturer (Partek Inc.). 
Differentially expressed genes with signal intensities in mutants > control were selected with 
>1.4-fold change and adjusted P-values <0.05. 
 
5.9 RNA isolation, cDNA synthesis, and qRT-PCR.  
Total RNA was isolated from LCM tissue using the Transcriptor High Fidelity Kit (Roche) 
according to the instructions of the manufacturer. cDNA was synthesized using a mixture 
of random nonamer primers and anchored poly-dT primers and SuperScript III RNase H 
reverse transcriptase (Invitrogen) according to the instructions of the manufacturer. qRT-




PCR was performed using SYBR green master mix (Applied Biosystems) and a 7500 Fast 
Real-Time PCR System (Applied Biosystems). Primers were designed using the Roche 
Universal ProbeLibrary website (http://qpcr.probefinder.com). Relative mRNA 
concentrations were normalized to Actin and Atp5b. Data were analyzed using qBase 
software version 1.3.5 (Center for Medical Genetics, Ghent University, Ghent, Belgium). 
 
5.9.1 Quantitative real-time PCR primers 
Pten 
Forward: 5'-TGGGGAAGTAAGGACCAG -3' 
Reverse: 5'-TATCTGCACGCTCTATAC -3' 
 
Neurotensin 
Forward: 5'-AGCTGGTGTGCCTGACTCTC -3' 
Reverse: 5'-CCAGGGCTCTCACATCTTCT -3' 
 
Fgf1 
Forward: 5'-CCGAAGGGCTTTTATACGG -3' 
Reverse: 5'-TCTTGGAGGTGTAAGTGTTATAATGG -3'  
 
Pleiotrophin 
Forward: 5'-CCTCAAGCGGAGTCAAAGAA -3'’ 
Reverse: 5'-CTTTTCCTGGTCCACAGACG -3' 
 
Timp3 
Forward: 5'-CACGGAAGCCTCTGAAAGTC -3' 
Reverse: 5'-TCCCACCTCTCCACAAAGTT -3' 
 
Inhba 
Forward: 5'-GGGAGTGATCCCTGGAAAC -3' 
Reverse: 5'-TCCTCTTCATGGTATTGGCACT -3' 
 
5.10 Mixed myelinating cocultures from mouse spinal cord  
Wild-type C57BL/6N mice were time-mated, with the day of plugging denoted as embryonic 
day 0.5 (E0.5), and embryos were collected on embryonic day 13.5 (E13.5). The spinal cord 
was dissected, and dissociated mechanically and enzymatically (0.25% trypsin, Invitrogen). 




Enzymatic activity was stopped by the addition of plating medium (50% DMEM, 25% horse 
serum, 25% Hanks balanced salt solution without Ca2+ and Mg2+) containing 2.5 µg/ml 
DNAse I. Cells were dissociated into a single cell suspension by triturating through 20- and 
23-gauge needles (4 and 2 times, respectively) and spun at 800 rpm for 5 min. The pellet 
was resuspended in plating medium. Dissociated spinal cord cells were plated initially onto 
poly-L-lysine (PLL, in boric acid buffer, pH8.4) coated coverslips at a density of 150.000 
cells/100 µl, which were then placed into a 35-mm Petri dish. The cells were left to attach 
for 2–3 hours, when 150 µl of plating medium and 500 µl of differentiation medium was 
added. This medium contained DMEM (4,500 mg/L glucose), 10 mg/ml biotin, 0.5% 
hormone mixture (1 mg/mL apotransferrin, 20 mM putrescine, 4 µM progesterone, and 6 
µM selenium), 50 nM hydrocortisone, and 10 g/ml insulin (all reagents were from Sigma). 
Cultures were maintained by replacing half of the medium with fresh medium three times a 
week. After 12 days in culture, cells were fed with differentiation medium with (or without) 
recombinant human Pdgf (100ng/ml), Sparcl1 (10ng/ml), Vegfc (100ng/ml), Fgf1 
(100ng/ml), Ptn (10ng/ml), Timp3 (100ng/ml), Tmsb4x (50ng/ml) or Activin A (100 ng/ml) 
and reduced concentration of Insulin (0.2 g/ml). Cultures were maintained for up to 25 
days in a humidified atmosphere of 5% CO2 at 37°C.  
 
5.11 Mixed primary oligodendrocyte cultures  
Mixed primary oligodendrocyte cultures were prepared from (7 pooled) spinal cords of P4 
mouse pups. Tissue chunks were incubated in 5 ml papain (200U) in papain buffer plus L-
cysteine for 1 hour at ~35°C with constant gassing (95% oxygen and 5% carbon dioxide). 
The papain reaction was stopped with plating medium (30% horse serum in DMEM) 
containing 2.5 µg/ml DNAse I. Cells were dissociated into a single cell suspension by 
triturating through 20 and 23 gauge needles (4 and 2 times, respectively), spun at 800 rpm 
for 5 min, and the pellet was resuspended in plating medium. Cells were plated at a 
concentration of 80,000 cells/100 µl plating medium onto PLL coated 11 mm diameter glass 
coverslips, in 35 mm diameter Petri-dishes (2 coverslips/dish). Two hours later, 
differentiation medium containing DMEM (4,500 mg/L glucose), 10 ng/ml biotin, 0.5% 
hormone mixture (1 mg/mL apotransferrin, 20 mM putrescine, 4 µM progesterone, and 6 
µM selenium), 50 nM hydrocortisone, and 10 g/ml insulin (all reagents from Sigma) was 
added to each 35 mm Petri dish to yield a mix of 50% plating medium: 50% differentiation 
medium. The following day all medium and myelin debris was removed from the coverslips 
by rinsing briefly in medium, and fresh differentiation medium was added to each 35 mm 
Petri dish, with or without human recombinant forms of Klotho (400ng/ml), Ptn (10ng/ml), 




Timp3 (100ng/ml) or Activin A (100ng/ml). Cells were fed every second day by replacing 
half the medium with fresh differentiation medium including the recombinant proteins. 
Cultures were maintained for 3 and 5 days in a humidified atmosphere of 5% CO2 at 37°C.  
 
5.12 Recombinant proteins 
Human recombinant proteins were Sparcl1, Vegfc, Klotho, Timp3, and Activin A (R&D 
Systems), Pdgf and Ptn (Sigma Aldrich), Tmsb4x (Novus Biologicals) and Fgf1 (Invitrogen). 
Recombinant proteins were dissolved in ddH2O. Individual aliquots were thawed only once 
and diluted in cell culture medium immediately before use. PI3K inhibitor LY294002 and 




Cells were fixed with 4% PFA for 5 min at 37°C. After fixation, cultures were washed in PBS 
three times, permeabilized with ice cold methanol for 5 min, and blocked in blocking buffer 
(2% fish skin gelatin, 2% FCS, 2% BSA in PBS) for 60 min. Primary antibodies (diluted in 
10% blocking buffer) were directed against GFAP (1:200, Novocastra, #NCL-GFAP-GA5), 
KI-67 (1:10, Dako, #M7249), MBP (1:200, Covance, #SMI-94R), Olig2 (1:200, kindly 
provided by J. Alberta, PMID: 15198128) SMI31 (1:1000, Covance, #SMI-31P), and APC-
CC1 (1:100, Calbiochem, #OP80) and incubated overnight at 4°C. Coverslips were washed 
in PBS three times. Corresponding secondary Alexa Fluor 488-, 555- and 633-conjunated 
antibodies (1:1000, Thermo Fisher Scientific, #A-28175, #A-21422, #A-27039 and #A-
21094) were diluted in 10% blocking buffer and added for 1 h. Coverslips were washed in 
ddH2O three times and mounted in Aqua-Poly/Mount (Polysciences). 
 
5.14 Morphometry  
Digitized overlapping light microscopic images (20x) were fused to a continuous image of a 
complete parasagittal cerebellum (Lateral, 0.12 mm) by using Zeiss Zen software and 
analyzed for absolute numbers of CNP+, CAII+, Olig2+, Iba1+, Mac-3+, and BrdU+ cells. 
The number of Iba1+ and Mac-3+ cells was normalized to the area of ML and GL, 
respectively. Endothelial cells positive for CD31 were traced with ImageJ and normalized 
to the area of the ML. To quantify MBP+ and GFAP+ areas, two ImageJ plugins for semi-
automated analysis were implemented (“MBP” and “GFAP” can be found on the included 




CD-ROM). Average diameter of hippocampal CA3 neuronal cell bodies of Nex-
CreERT2*PtenloxP/loxP mice was determined by using ImageJ software. Two independent 
sections per mouse and staining were quantified. In cell culture experiments, the 
differentiation and proliferation state of oligodendrocyte lineage cells was analyzed within 
the given fields of 11 randomly taken images (20x) per coverslip (mixed myelinating 
cultures: myelination assay, 3-11 independent experiments with 2 coverslips per condition; 
proliferation assay, 3-11 independent experiments with 1 coverslip per condition; mixed 
primary oligodendrocyte cultures: 3-5 independent experiments with 2 coverslips per 
condition). For quantitative assessment of in vitro myelination a “myelination index” was 
calculated by dividing the MBP+ area (as identified by generating a “mask” outlining the 
myelin sheaths; “CoCultureMBP”, can be found on the included CD-ROM). by the axonal 
area (Smi31+ axons; “CoCultureSmi31”, can be found on the included CD-ROM). For the 
proliferation assay the percentage of semi-automatically quantified Olig2+ cells was 
determined in relation to all DAPI+ cells (“CoCultureOlig2 and “CoCultureDAPI”, can be 
found on the included CD-ROM) and the number of Ki67+, Olig2+ cells was set in relation to 
the total number of Olig2+ cells. For the differentiation assay, the percentage of postmitotic 
oligodendrocytes was determined by quantifying and dividing the numbers of CC1+ cells by 
the total number of Olig2+ oligodendrocyte lineage cells. All analyses were performed in a 
single blinded fashion towards the investigator who was unaware of the treatment regimen. 
 
5.15 G-ratio measurement 
Digitized images (magnification 7000x) of ultrathin cerebellum lobe 5 sections were used to 
determine the numbers of myelinated axons, axon calibers and g-ratios (>100 randomly 
chosen myelinated axons in the molecular layer). g-ratios were determined by dividing the 
inner myelin diameter by the diameter of the entire fiber. Quantitations were performed from 
≥3 age-matched male mice per genotype and age.  
 
5.16 Protein analysis 
Cerebellum lysates were homogenized in lysis-buffer (50 mM HEPES, pH 7.5, 150 mM 
NaCl, 1.5 mM MgCl2, 5 mM EGTA, 10% glycerol, 1% triton X-100, 2mM Na3VO4) 
containing phosphatase (PhosSTOP Inhibitor Cocktail, Roche, Basel, Switzerland) and 
protease (Complete tablets, Roche, Basel, Switzerland) inhibitors using an Ultraturrax (T8, 
Ika, Staufen, Germany) at highest settings (30–60 s). After incubation for 15 min on ice 
insoluble material was removed by centrifugation at 16.000 g, 4°C for 15 min. For 




Westernblot analysis, 10 µg of protein lysate was size-separated on 12% of SDS-
polyacrylamide gels and blotted onto PVDF membranes (HybondTM-P, Amersham 
Biosciences, UK) by Bio-Rad western blotting method. Membranes were blocked in 5% milk 
powder (in PBS) for 1h at room temperature. Primary antibodies were directed against p-
AKT (Cell Signaling, mRb, 1:1000, #4060), AKT (Cell Signaling, mRb, 1:1000, #4691), 
PTEN (Cell Signaling, mRb, 1:1000, #9188), p-PDK1 (Cell Signaling, mRb, 1:1000, #3438), 
p-mTOR (Cell Signaling, mRb, 1:1000, #5536), p-S6 (Cell Signaling, mRb, 1:1000, #4858), 
and Actin (Sigma–Aldrich, mM, 1:1000, #A3853). Antibodies were diluted in blocking buffer 
and incubated overnight at 4°C. Membranes were washed 3 x 10 min in TBS-T buffer (50 
mM Tris-HCl, pH 7.4, 150 mM NaCl and 0.05% Tween-20), followed by an incubation with 
horse-radish peroxidase-conjugated secondary antibodies (1:5000, Dianova, #111-035-
003, #115-035-003). After three more washing steps with TBS-T buffer, immunoreactive 
proteins were detected with an enhanced chemiluminescence kit (Western LightningTM, 
Westernblot Chemiluminescence Reagent Plus, PerkinElmer Life Sciences, Waltham, MA) 
according to the manufacturer’s instructions. 
 
5.17 Statistical analysis 
For Power analysis the software G*Power Version 3.1.7. was used. Power analyses were 
performed before conducting experiments (a priori). Adequate Power (1 – beta-error) was 
defined as ≥ 80% and the alpha error as 5%. The sample size was calculated with the 
following pre-specified effect sizes: 1. mRNA expression analysis: effect size d of 
approximately 2.5 (estimated mean difference of 50% and standard deviation of 15%). 2. 
Analysis of mature oligodendrocyte numbers in GL (effect size d of approximately 3.5, 
estimated mean difference of 30% and standard deviation of 10%) and ML (effect size d of 
approximately 6.5, estimated mean difference of 400% and standard deviation of 30%) and 
myelinated area in the ML of wildtype and Pten mutants (effect size d of approximately 6.0, 
estimated mean difference of 170% and standard deviation of 40%). 3. Proliferation analysis 
of oligodendrocyte lineage cells: effect size d of approximately 9.0 (estimated mean 
difference of 330% and standard deviation of 15%). 4. In vivo analysis of candidate genes. 
Analysis of mature oligodendrocyte numbers: effect size d of approximately 5.5 (estimated 
mean difference of 30% and standard deviation of 15%). Analysis of myelinated area: effect 
size d of approximately 4.0 (estimated mean difference of 30% and standard deviation of 
13%). Proliferation analysis of oligodendrocyte lineage cells: effect size d of approximately 
3.5 (estimated mean difference of 20% and standard deviation of 10%). Analysis of (i) 
myelinated and (ii) unmyelinated pf diameters: (i) effect size d of approximately 2.6 
(estimated mean difference of 20% and standard deviation of 13%). (ii) Effect size d of 




approximately 1.5 (estimated mean difference of 15% and standard deviation of 13%). G-
ratio analysis: effect size d of approximately 4.5 (estimated mean difference of 6% and 
standard deviation of 2%). 5. Microglia (ML: Effect size d of approximately 4.7, estimated 
mean difference of 100% and standard deviation of 20%; GL: effect size d of approximately 
1.2, estimated mean difference of 10% and standard deviation of 5%), astrocytes (ML: effect 
size d of approximately 4.0, estimated mean difference of 150% and standard deviation of 
15%; GL: effect size d of approximately 1.3, estimated mean difference of 10% and standard 
deviation of 5%) and vascular endothelia cells (effect size d of approximately 3.7, estimated 
mean difference of 40% and standard deviation of 15%) in Pten mutant mice. 6. Microglia 
(ML: effect size d of approximately 1.0, estimated mean difference of 10% and standard 
deviation of 9%; GL: effect size d of approximately 1.3, estimated mean difference of 10% 
and standard deviation of 7%) and astrocytes (ML: effect size d of approximately 1.2, 
estimated mean difference of 20% and standard deviation of 15%; GL: effect size d of 
approximately 1.1, estimated mean difference of 10% and standard deviation of 5%) in 
NEX-CreERT2*PtenloxP/loxP mice. 7. Average diameter of hippocampal CA3 neuronal cell 
bodies from Nex-CreERT2*PtenloxP/loxP mice: effect size d of approximately 12.0 (estimated 
mean difference of 25% and standard deviation of 2%) 8. In vitro analysis of candidate 
factors. Analysis of oligodendrocyte lineage cell numbers: effect size d of approximately 4.0 
(estimated mean difference of 80% and standard deviation of 30%). Proliferation analysis: 
effect size d of approximately 2.3 (estimated mean difference of 60% and standard deviation 
of 36%). Myelination index: effect size d of approximately 2.0 (estimated mean difference 
of 65% and standard deviation of 50%). Analysis of oligodendrocyte differentiation: effect 
size d of approximately 9.0 (estimated mean difference of 40% and standard deviation of 
10%). For electrophysiology experiments we determined the sample size by utilizing 
previous data distributions. 
 
Data are expressed as means +/- s.e.m. In order to select appropriate statistical tests all 
data have been tested for normal distribution with Kolmogorov-Smirnov test or Shapiro-Wilk 
test. For normally distributed data with comparable variances we used two-tailed unpaired 
Student’s t-tests and Chi-square tests to determine the statistical significance between two 
groups. For data not showing normal distribution or in case that no normality test could be 
conducted the nonparametric Wilcoxon matched pairs test was applied. Data sets 
containing more than two groups were tested by applying analysis of variance (ANOVA) 
and Bonferroni post hoc test. Analysis of co-variance (ANCOVA) was used to analyse the 
differences between slopes of regression lines. Applied statistical tests are indicated in the 
respective figure legends. Statistical differences were considered significant when p<0.05 




(*p<0.05, **p<0.01, ***p<0.001) and tests and fitting of regression lines were performed by 
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